Archive for May, 2020

BOSTON, April 28, 2020 /PRNewswire/ -- In their brand new report "COVID-19 Diagnostics", global market research firm IDTechEx benchmarked more than 100 commercial devices across various technologies, providing a deep insight into the technology trends and biotech innovations surrounding the COVID-19 global response. For more information on this report, please visit http://www.IDTechEx.com/COVID.

"You cannot fight a fire blindfolded. And we cannot stop this pandemic if we don't know who is infected. We have a simple message for all countries: test, test, test. Test every suspected case" - Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO).

Viruses were once known as "contagious living fluids", strange infectious substances capable of slipping through the finest of filters unnoticed. SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic is indeed slipping through every layer of society, leaving behind severe public health and economic crises. Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug.

Since the full genome sequencing of the SARS-CoV-2, many national laboratories have identified the regions of the genome amenable for genetic testing. The golden standard adopted by national laboratories around the world following the WHO protocol to detect the virus in individuals, is based on detecting genetic material specific to SARS-CoV-2 viruses in a person's nasopharyngeal secretions. The main tool for such genetic tests is the Reverse Transcription Polymerase Chain Reaction (RT-PCR). Primer strands that hybridise specifically to the SARS-CoV-2 genome, together with fluorescent probes, help amplify and detect the viral load present in a patient. RT-PCR, normally performed in a real-time quantitative qRT-PCR machine for live fluorescent read-out, constitutes the core element of the testing effort being deployed at the moment across the globe. Clinical laboratories with the necessary equipment and technical know-how to perform RT-PCR are leading this diagnosis effort.

However, not all countries are prepared, neither logistically or with enough equipment and capacity. An important bottleneck is the short supply of certain ancillary reagents, such as RNA extraction kits. The shortage of such supplies and long processing time, has led to many laboratories to try to circumvent some steps in the protocol and to come up with new approaches to reach the testing targets that have been set by policymakers and healthcare officials.

The need for universal and massive testing across the population has led to a race for technology innovations for COVID-19 diagnostics. Point-of-care molecular diagnostics (POC MDx) are portable devices that perform molecular diagnosis away from central labs. Microfluidics is the key technology behind POC MDx, which controls the motion of small amounts of fluids in microchannels. Microfluidic cartridges enable the miniaturisation of devices and introduces automation in the sample handling and detection processes. Some POC MDx devices use isothermal amplification of nucleic acid as an alternative to PCR devices. Isothermal amplifaction bypasses the need of thermal cycling and reduces the detection time to just 5 min. Various isothermal amplifaction methods have been adopted for COVID-19 diagnostics. Complex design and unspecific amplification hinder the widespread use of this method. "COVID-19 Diagnostics" provides a deep insight and comparison into the technologies, innovations and current progress on POC MDx and isothermal amplification.

Apart from the time consuming thermal cycling, real-time fluorescent detection is another limitation for low-cost and portable diagnosis tools. Lateral flow assays, electrochemical detection and microbead-based arrays are integrated with PCR to detect the amplified genetic products. These hybrid systems enable faster, cheaper and palm-size devices at the expense of sensitivity and specificity. More recently, CRISPR-Cas (gene-editing tool based on speficifc gene recognition) and DNA sequencing techniques show the potential for highly sensitive and selective hybrid systems, as highlighted in "COVID-19 Diagnostics". For more information on this report, please visit http://www.IDTechEx.com/COVID or for the full portfolio of medical technology research available from IDTechEx please visit http://www.IDTechEx.com/LifeSci.

Resonating with the message of the WHO director general: "test, test and test", these innovations offer the tools to stop the current outbreak, as well as to prevent future outbreaks, by effective diagnostics and surveillance testing.

IDTechEx guides your strategic business decisions through its Research, Consultancy and Event products, helping you profit from emerging technologies. For more information on IDTechEx Research and Consultancy, contact research@IDTechEx.com or visit http://www.IDTechEx.com.

Media Contact:Jessica AbineriMarketing Coordinator press@IDTechEx.com+44(0)1223-812300

View original content to download multimedia:http://www.prnewswire.com/news-releases/fighting-the-covid-19-fire-with-molecular-diagnostics-new-idtechex-report-on-innovations-301048428.html

SOURCE IDTechEx

See the rest here:
Fighting The COVID-19 Fire With Molecular Diagnostics, New IDTechEx Report on Innovations - P&T Community

Global CNS Gene Therapy Market Analysis

Persistence Market Research, in a recently published market study, offers valuable insights related to the overall dynamics of the CNS Gene Therapy market in the current scenario. Further, the report assesses the future prospects of the CNS Gene Therapy by analyzing the various market elements including the current trends, opportunities, restraints, and market drivers. The COVID-19 analysis section within the report offers timely insights regarding the impact of the global pandemic on the market. The presented study also offers data regarding the business and supply chain continuity strategies that are likely to assist stakeholders in the long-run.

As per the report, the CNS Gene Therapy market is set to grow at a CAGR of ~XX% over the forecast period (2019-2029) and exceed a value of ~US$ XX by the end of 2029. Some of the leading factors that are expected to drive the growth of the market include, focus towards research and development, innovations, and evolving consumer preferences among others.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/27514

Regional Outlook

The report scrutinizes the prospects of the CNS Gene Therapy market in different geographical regions. The scope of innovation, consumer behavior, and regulatory framework of each region is thoroughly analyzed in the presented study.

Distribution-Supply Channel Assessment

The report provides a thorough analysis of the different distribution channels adopted by market players in the global CNS Gene Therapy market along with the market attractiveness analysis of each distribution channel. The impact of the COVID-19 pandemic on the different distribution channels is enclosed in the report.

Product Adoption Analysis

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/27514

The report aims to address the following pressing questions related to the CNS Gene Therapy market:

Key Takeaways from the CNS Gene Therapy Market Report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/27514

Why Companies Trust PMR?

See the original post here:
CNS Gene Therapy Market to Slip Due to Delays in Production Amidst Coronavirus Outbreak Cole Reports - Cole of Duty

CAMBRIDGE, Mass., May 1, 2020 /PRNewswire/ --Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, today announced it will share the architecture and components of its Safe Workplace Function Tool (SWFT) Productivity Solution. The SWFT Solution was designed in response to the COVID19 pandemic to support a safe work environment while maintaining productivity in the lab.

The SWFT Solution is a web-based application built and integrated into Microsoft 365 that allows scientists to view and schedule lab-based activities including by date, time and lab location. SWFT promotes collaboration and coordination between teams by predicting scheduling and occupancy conflicts, which allows team members to adjust their schedules to promote social distancing in the lab and office.

"The SWFT Solution has enabled Obsidian to continue to generate critical data across our cytoDRiVE development programs, while maximizing the safety of our staff," stated Catherine Stehman-Breen, M.D., Chief Research and Development Officer at Obsidian. "We have already shared this technology with large pharmaceutical and small biotechnology companies who are interested in our SWFT Solution to get their labs back up and running. We believe that it is more important than ever before to leverage one another's expertise in order to overcome challenges as we work tirelessly to deliver meaningful outcomes to patients in need."

To create Obsidian's bespoke application, (1) a capacity analysis was conducted, taking into consideration lab space and occupancy levels, and (2) in collaboration with scientists, workflow recommendations were implemented to determine an appropriate shift schedule. These steps facilitated the development of a solution that enabled scientists to plan their experiments with specific lab locations and shifts, as well as be alerted to and prevent any over-capacity issues. Obsidian implemented four three-hour lab blocks, with thirty-minutes of cleaning time between blocks, over a seven-day work week, to ensure that coronavirus-related safety recommendations were met.

Celeste Richardson, Ph.D., Vice President of Cell Therapy of Obsidian, stated, "We have a commitment to our employees to keep the health and safety of our employees top of mind while they work to bring innovative therapies to patients. The development of the SWFT Solution perfectly demonstrates Obsidian's culture of teamwork, determination and innovation."

Obsidian's IT Partner, TRNDigital, is continuing to iterate the tool to ensure it continues to meet scientists' needs and can be made available to others. The solution has been expanded to include density planning in the Obsidian offices. In addition, the SWFT Solution is scalable and flexible to other laboratory setups.

The SWFT solution was developed in-house by Henry Rogalin, Data Scientist, under the leadership of Nic Betts, Head of IT and Facilities, and in collaboration with a safety and facilities capacity team led by Jillian Giguere, Senior Manager of Laboratory Operations, Facilities, and EHS. For more information on SWFT, submit this inquiry form. Informational sessions and training will be hosted as requested.

About Obsidian TherapeuticsObsidian Therapeutics is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company's initial applications focus on developing novel cell therapies for the treatment of cancer. Obsidian is headquartered in Cambridge, Mass. For more information, please visit http://www.obsidiantx.com.

Media Contact:Maggie BellerRusso Partners, LLCMaggie.beller@russopartnersllc.com646-942-5631

View original content to download multimedia:http://www.prnewswire.com/news-releases/obsidian-therapeutics-develops-and-shares-safe-workplace-productivity-solution-in-response-to-covid19-301050820.html

SOURCE Obsidian Therapeutics

See the rest here:
Obsidian Therapeutics Develops and Shares Safe Workplace Productivity Solution in Response to COVID19 - P&T Community

Analysis of the Global Hemophilia Gene Therapy Market

The report on the global Hemophilia Gene Therapy market reveals that the market is expected to grow at a CAGR of ~XX% during the considered forecast period (2019-2029) and estimated to reach a value of ~US$XX by the end of 2029. The latest report is a valuable tool for stakeholders, established market players, emerging players, and other entities to devise effective strategies to combat the impact of COVID-19

Further, by leveraging the insights enclosed in the report, market players can devise concise, impactful, and highly effective growth strategies to solidify their position in the Hemophilia Gene Therapy market.

Research on the Hemophilia Gene Therapy Market Addresses the Following Queries

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2640005&source=atm

Competitive Landscape

The competitive landscape section offers valuable insights related to the business prospects of leading market players operating in the Hemophilia Gene Therapy market. The market share, product portfolio, pricing strategy, and growth strategies adopted by each market player is included in the report. The major steps taken by key players to address the business challenges put forward by the novel COVID-19 pandemic is discussed in the report.

Regional Landscape

The regional landscape section provides a deep understanding of the regulatory framework, current market trends, opportunities, and challenges faced by market players in each regional market. The various regions covered in the report include:

End-User Assessment

The report bifurcates the Hemophilia Gene Therapy market based on different end users. The supply-demand ratio and consumption volume of each end-user is accurately depicted in the report.

Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Hemophilia Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Hemophilia Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Hemophilia Gene Therapy market.The following players are covered in this report:Spark TherapeuticsUltragenyxShire PLCSangamo TherapeuticsBioverativBioMarinuniQureFreeline TherapeuticsHemophilia Gene Therapy Breakdown Data by TypeHemophilia AHemophilia BHemophilia Gene Therapy Breakdown Data by ApplicationHemophilia A Gene TherapyHemophilia B Gene Therapy

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2640005&source=atm

Essential Findings of the Hemophilia Gene Therapy Market Report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2640005&licType=S&source=atm

Go here to see the original:
Assessing the Fallout From the Coronavirus Pandemic Hemophilia Gene Therapy to Discern Steadfast Expansion During 2019-2053 - amitnetserver

Sarepta Therapeutics, Inc.s (NASDAQ:SRPT): Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The US$9.2b market-cap company announced a latest loss of -US$715.1m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on SRPTs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for SRPTs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Sarepta Therapeutics

According to the 22 industry analysts covering SRPT, the consensus is breakeven is near. They expect the company to post a final loss in 2021, before turning a profit of US$716m in 2022. Therefore, SRPT is expected to breakeven roughly 2 years from today. How fast will SRPT have to grow each year in order to reach the breakeven point by 2022? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, SRPT may become profitable much later than analysts predict.

Im not going to go through company-specific developments for SRPT given that this is a high-level summary, but, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing I would like to bring into light with SRPT is its relatively high level of debt. Generally, the rule of thumb is debt shouldnt exceed 40% of your equity, which in SRPTs case is 83%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are key fundamentals of SRPT which are not covered in this article, but I must stress again that this is merely a basic overview. For a more comprehensive look at SRPT, take a look at SRPTs company page on Simply Wall St. Ive also compiled a list of key factors you should look at:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

See the original post here:
When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Become Profitable? - Simply Wall St

DetailsCategory: AntibodiesPublished on Friday, 01 May 2020 15:04Hits: 468

Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies

PRINCETON, NJ & CAMBRIDGE, MA, USA I April 30, 2020 IBristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Reblozyl (luspatercept) for the treatment of:

This CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients. The safety and efficacy results provided in the application are from the pivotal Phase 3 MEDALIST and BELIEVE studies, evaluating the ability of Reblozyl to effectively address anemia associated with MDS and beta thalassemia, respectively.

"Patients with myelodysplastic syndromes who experience anemia have limited treatment options, and some have been shown to not respond to available erythropoietin-based therapies," said Uwe Platzbecker, M.D., Head of Clinic and Policlinic for Hematology and Cell Therapy, Leipzig University Hospital and lead investigator of the MEDALIST study. If approved, the introduction of a new class of therapy in Reblozyl could provide a promising option to help relieve patients from the burden of regular transfusions to manage their disease.

Todays positive CHMP opinion of Reblozyl is an important milestone for adult beta thalassemia patients in the EU who have limited treatment options to address anemia, a serious consequence of the disease, said Maria Domenica Cappellini, M.D., Professor of Medicine, University of Milan, Fondazione IRCCS Ca Granda and lead investigator of the BELIEVE study. Reblozyl has the potential to significantly decrease the number of red blood cell transfusions patients need.

This decision by the CHMP is an important step towards making this first-in-class therapy an option for eligible patients with anemia due to beta thalassemia or myelodysplastic syndromes, said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb. We, and our partners at Acceleron, look forward to the opportunity to make this treatment option available in the EU and are extremely appreciative of the patients, families and individuals who continue to help us progress important research in a range of serious diseases.

About MEDALIST

MEDALIST is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and efficacy of luspatercept plus best supportive care (BSC) versus placebo plus BSC in adults with IPSS-R-defined very low-, low- or intermediate-risk non-del(5q) myelodysplastic syndromes (MDS). All patients were red blood cell (RBC) transfusion-dependent and were either refractory or intolerant to prior erythropoiesis stimulating agent (ESA) therapy, or were ESA nave and unlikely to respond due to endogenous serum erythropoietin levels of 200 U/L, and had no prior treatment with disease modifying agents. Results of the MEDALIST trial were first presented during the Plenary Session of the 2018 American Society of Hematology (ASH) Annual Meeting and were selected for the Best of ASH. The New England Journal of Medicine published the MEDALIST trial results in January 2020.

About MDS

MDS are a group of closely related blood cancers characterized by ineffective production of healthy red blood cells, white blood cells and platelets, which can lead to anemia and frequent or severe infections. People with MDS who develop anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation. Frequent transfusions are associated with an increased risk of iron overload, transfusion reactions and infections. There are approximately 50,000 patients with MDS in the EU5 countries.

About BELIEVE

BELIEVE is a Phase 3, randomized, double-blind, placebo-controlled multi-center study comparing luspatercept plus BSC versus placebo plus BSC in adults who require regular RBC transfusions (6-20 RBC units per 24 weeks with no transfusion-free period greater than 35 days during that period) due to beta thalassemia. Results of the BELIEVE trial were first presented at the 2018 ASH Annual Meeting and selected for the Best of ASH. The New England Journal of Medicine published the BELIEVE trial results in March 2020.

About Beta Thalassemia

Beta thalassemia is an inherited blood disorder caused by a genetic defect in hemoglobin. The disease is associated with ineffective erythropoiesis, which results in the production of fewer and less healthy RBCs, often leading to severe anemia a condition that can be debilitating and can lead to more severe complications for patients as well as other serious health issues. Treatment options for anemia associated with beta thalassemia are limited, consisting mainly of frequent RBC transfusions that have the potential to contribute to iron overload, which can cause serious complications such as organ damage. Across the United States, Germany, France, Italy, Spain and the United Kingdom, there are approximately 17,000 patients with beta thalassemia.

About Reblozyl

Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models. Bristol Myers Squibb and Acceleron are jointly developing Reblozyl as part of a global collaboration. Reblozyl is currently approved in the U.S. for the treatment of:

Reblozyl is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Please see full Prescribing Information for REBLOZYL

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb Company and Juno Therapeutics, a Bristol-Myers Squibb Company.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol Myers Squibb, are co-promoting REBLOZYL (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelofibrosis. Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

For more information, please visit http://www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

SOURCE: Bristol-Myers Squibb

More here:
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |...

In the first article we looked at face masks (when do you need to where one and why?); in the second we looked at disinfection (which disinfectants work best?); and the third topic was social distancing (why is 2 metres considered to be a safe distance?) The subject matter for the fourth article was the lockdown and whether the idea of an 'immunity passport' is a good idea (which is probably isn't). For the firth dive into COVID-19 subjects, we look at where we are with vaccine development, what the most promising antivirals are, and what do the different tests for coronavirus do and how do they vary?In this article, the topic is testing, vaccines and other efforts to help to combat the disease.

A laboratory technician works on coronavirus samples at "Fire Eye" laboratory in Wuhan

STR, STR, AFP

A fluorescent antibody (DFA) stain reveals the presence of rabies viral antigen in a tissue sample harvested from a mandibular salivary gland, suspected of being infected with rabies.

CDC/PHIL

A nurse wearing blue gloves administers a vaccine into a male patient's arm.

Rhoda Baer (National Institutes of Health)

Images of COVID-19 released by US science agencies

John SAEKI, AFP

France has now detected a total of 11 cases of the novel coronavirus

JEFF PACHOUD, AFP/File

This opinion article was written by an independent writer. The opinions and views expressed herein are those of the author and are not necessarily intended to reflect those of DigitalJournal.com

Go here to read the rest:
Op-Ed: Where are we with the coronavirus vaccine? - Digital Journal

Complete study of the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market include , BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1695571/global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market

Segmental Analysis

The report has classified the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry.

Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Segment By Type:

, BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Segment By Application:

, BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market include , BioReliance, Cobra Biologics, Oxford BioMedica, UniQure, FinVector, MolMed, MassBiologics, Richter-Helm, FUJIFILM Diosynth Biotechnologies, Lonza, Aldevron, Eurogentec, Cell and Gene Therapy Catapult, Biovian, Brammer Bio, VGXI, PlasmidFactory, bluebird bio, Novasep, Spark Therapeutics, Vigene Biosciences

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3350): https://www.qyresearch.com/settlement/pre/7293801c1b080b1ca9df50a1a2dc1483,0,1,global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market

TOC

1 Market Overview of Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview1.1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Product Scope1.1.2 Market Status and Outlook1.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Region (2015-2026)1.4 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Region (2015-2020)1.5 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size Forecast by Region (2021-2026)1.6 Key Regions Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.1 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.2 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.3 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.5 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Industry Impact1.7.1 How the Covid-19 is Affecting the Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Industry1.7.1.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Business Impact Assessment Covid-191.7.1.2 Supply Chain Challenges1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-191.7.3.1 Government Measures to Combat Covid-19 Impact1.7.3.2 Proposal for Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Players to Combat Covid-19 Impact 2 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview by Type2.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Type: 2015 VS 2020 VS 20262.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Type (2015-2020)2.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Forecasted Market Size by Type (2021-2026)2.4 AAV2.5 Adenoviral2.6 Lentiviral2.7 Retroviral2.8 Plasmid DNA2.9 Other Vectors 3 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Overview by Type3.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application: 2015 VS 2020 VS 20263.2 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Historic Market Size by Application (2015-2020)3.3 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Forecasted Market Size by Application (2021-2026)3.4 Cancers3.5 Inherited Disorders3.6 Viral Infections3.7 Others 4 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Competition Analysis by Players4.1 Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing as of 2019)4.3 Date of Key Manufacturers Enter into Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market4.4 Global Top Players Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Headquarters and Area Served4.5 Key Players Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Product Solution and Service4.6 Competitive Status4.6.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 BioReliance5.1.1 BioReliance Profile5.1.2 BioReliance Main Business and Companys Total Revenue5.1.3 BioReliance Products, Services and Solutions5.1.4 BioReliance Revenue (US$ Million) (2015-2020)5.1.5 BioReliance Recent Developments5.2 Cobra Biologics5.2.1 Cobra Biologics Profile5.2.2 Cobra Biologics Main Business and Companys Total Revenue5.2.3 Cobra Biologics Products, Services and Solutions5.2.4 Cobra Biologics Revenue (US$ Million) (2015-2020)5.2.5 Cobra Biologics Recent Developments5.3 Oxford BioMedica5.5.1 Oxford BioMedica Profile5.3.2 Oxford BioMedica Main Business and Companys Total Revenue5.3.3 Oxford BioMedica Products, Services and Solutions5.3.4 Oxford BioMedica Revenue (US$ Million) (2015-2020)5.3.5 UniQure Recent Developments5.4 UniQure5.4.1 UniQure Profile5.4.2 UniQure Main Business and Companys Total Revenue5.4.3 UniQure Products, Services and Solutions5.4.4 UniQure Revenue (US$ Million) (2015-2020)5.4.5 UniQure Recent Developments5.5 FinVector5.5.1 FinVector Profile5.5.2 FinVector Main Business and Companys Total Revenue5.5.3 FinVector Products, Services and Solutions5.5.4 FinVector Revenue (US$ Million) (2015-2020)5.5.5 FinVector Recent Developments5.6 MolMed5.6.1 MolMed Profile5.6.2 MolMed Main Business and Companys Total Revenue5.6.3 MolMed Products, Services and Solutions5.6.4 MolMed Revenue (US$ Million) (2015-2020)5.6.5 MolMed Recent Developments5.7 MassBiologics5.7.1 MassBiologics Profile5.7.2 MassBiologics Main Business and Companys Total Revenue5.7.3 MassBiologics Products, Services and Solutions5.7.4 MassBiologics Revenue (US$ Million) (2015-2020)5.7.5 MassBiologics Recent Developments5.8 Richter-Helm5.8.1 Richter-Helm Profile5.8.2 Richter-Helm Main Business and Companys Total Revenue5.8.3 Richter-Helm Products, Services and Solutions5.8.4 Richter-Helm Revenue (US$ Million) (2015-2020)5.8.5 Richter-Helm Recent Developments5.9 FUJIFILM Diosynth Biotechnologies5.9.1 FUJIFILM Diosynth Biotechnologies Profile5.9.2 FUJIFILM Diosynth Biotechnologies Main Business and Companys Total Revenue5.9.3 FUJIFILM Diosynth Biotechnologies Products, Services and Solutions5.9.4 FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) (2015-2020)5.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments5.10 Lonza5.10.1 Lonza Profile5.10.2 Lonza Main Business and Companys Total Revenue5.10.3 Lonza Products, Services and Solutions5.10.4 Lonza Revenue (US$ Million) (2015-2020)5.10.5 Lonza Recent Developments5.11 Aldevron5.11.1 Aldevron Profile5.11.2 Aldevron Main Business and Companys Total Revenue5.11.3 Aldevron Products, Services and Solutions5.11.4 Aldevron Revenue (US$ Million) (2015-2020)5.11.5 Aldevron Recent Developments5.12 Eurogentec5.12.1 Eurogentec Profile5.12.2 Eurogentec Main Business and Companys Total Revenue5.12.3 Eurogentec Products, Services and Solutions5.12.4 Eurogentec Revenue (US$ Million) (2015-2020)5.12.5 Eurogentec Recent Developments5.13 Cell and Gene Therapy Catapult5.13.1 Cell and Gene Therapy Catapult Profile5.13.2 Cell and Gene Therapy Catapult Main Business and Companys Total Revenue5.13.3 Cell and Gene Therapy Catapult Products, Services and Solutions5.13.4 Cell and Gene Therapy Catapult Revenue (US$ Million) (2015-2020)5.13.5 Cell and Gene Therapy Catapult Recent Developments5.14 Biovian5.14.1 Biovian Profile5.14.2 Biovian Main Business and Companys Total Revenue5.14.3 Biovian Products, Services and Solutions5.14.4 Biovian Revenue (US$ Million) (2015-2020)5.14.5 Biovian Recent Developments5.15 Brammer Bio5.15.1 Brammer Bio Profile5.15.2 Brammer Bio Main Business and Companys Total Revenue5.15.3 Brammer Bio Products, Services and Solutions5.15.4 Brammer Bio Revenue (US$ Million) (2015-2020)5.15.5 Brammer Bio Recent Developments5.16 VGXI5.16.1 VGXI Profile5.16.2 VGXI Main Business and Companys Total Revenue5.16.3 VGXI Products, Services and Solutions5.16.4 VGXI Revenue (US$ Million) (2015-2020)5.16.5 VGXI Recent Developments5.17 PlasmidFactory5.17.1 PlasmidFactory Profile5.17.2 PlasmidFactory Main Business and Companys Total Revenue5.17.3 PlasmidFactory Products, Services and Solutions5.17.4 PlasmidFactory Revenue (US$ Million) (2015-2020)5.17.5 PlasmidFactory Recent Developments5.18 bluebird bio5.18.1 bluebird bio Profile5.18.2 bluebird bio Main Business and Companys Total Revenue5.18.3 bluebird bio Products, Services and Solutions5.18.4 bluebird bio Revenue (US$ Million) (2015-2020)5.18.5 bluebird bio Recent Developments5.19 Novasep5.19.1 Novasep Profile5.19.2 Novasep Main Business and Companys Total Revenue5.19.3 Novasep Products, Services and Solutions5.19.4 Novasep Revenue (US$ Million) (2015-2020)5.19.5 Novasep Recent Developments5.20 Spark Therapeutics5.20.1 Spark Therapeutics Profile5.20.2 Spark Therapeutics Main Business and Companys Total Revenue5.20.3 Spark Therapeutics Products, Services and Solutions5.20.4 Spark Therapeutics Revenue (US$ Million) (2015-2020)5.20.5 Spark Therapeutics Recent Developments5.21 Vigene Biosciences5.21.1 Vigene Biosciences Profile5.21.2 Vigene Biosciences Main Business and Companys Total Revenue5.21.3 Vigene Biosciences Products, Services and Solutions5.21.4 Vigene Biosciences Revenue (US$ Million) (2015-2020)5.21.5 Vigene Biosciences Recent Developments 6 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application6.1 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)6.2 North America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 7 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application7.1 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)7.2 Europe Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 8 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application8.1 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)8.2 China Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 9 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application9.1 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 10 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application10.1 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)10.2 Latin America Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 11 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing by Players and by Application11.1 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Size by Application (2015-2020) 12 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the rest here:
Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020: Analysis By Regional Outlook, Competitive Landscape, Strategies And...

CHELMSFORD May 1, 2020 (Thomson StreetEvents) -- Edited Transcript of Brooks Automation Inc earnings conference call or presentation Thursday, April 30, 2020 at 8:30:00pm GMT

* Lindon G. Robertson

Brooks Automation, Inc. - Executive VP & CFO

Brooks Automation, Inc. - Director of IR

* Stephen S. Schwartz

* J. Ho

Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector

* Jacob K. Johnson

Crdit Suisse AG, Research Division - MD, Global Technology Strategist and Global Technology Sector Head

Janney Montgomery Scott LLC, Research Division - MD, Head of Healthcare Research & Senior Equity Research Analyst

Greetings, and welcome to the Brooks Automation Q2 2020 Financial Results. (Operator Instructions) As a reminder, this conference is being recorded Thursday, April 30, 2020. I would now like to turn the conference over to Mark Namaroff. Please go ahead.

Mark Namaroff, Brooks Automation, Inc. - Director of IR [2]

Thank you, Malaika. Good afternoon everyone on the line today. We hope everyone is staying healthy in this environment. We'd like to welcome you to our earnings conference call for the second quarter of fiscal 2020. Our Q2 earnings press release was issued after the close of the market today and it is available on our Investor Relations website located at brooks.investorroom.com, as are the supplementary PowerPoint slides that we'll be using during the prepared remarks.

I would like to remind everyone that during the course of the call today, we will be making a number of forward-looking statements within the meaning of the Private Litigation and Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I would refer you to the section of our earnings release titled Safe Harbor Statement, the safe harbor slide on our aforementioned PowerPoint presentation on our website, and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today.

We would also refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe non-GAAP measures provide an additional way of viewing aspects of our operations and performance. But when considered with GAAP financial results, the reconciliation of GAAP measures, and a reconciliation of GAAP measures, they provide an even more complete understanding of the Brooks business. Non-GAAP measures should not be relied upon to the exclusion of GAAP measures themselves.

On the call with me today is our President and Chief Executive Officer, Steve Schwartz, and Executive Vice President and Chief Financial Officer, Lindon Robertson. We will open the call up with remarks from Steve on the highlights of the second quarter, and then Lindon will provide a more detailed look into our financial results for the quarter and our outlook for the third fiscal quarter of 2020. We will then have time to take your questions at the end of our prepared remarks.

And with that, now I'd like to turn the call over to our CEO, Steve Schwartz.

--------------------------------------------------------------------------------

Stephen S. Schwartz, Brooks Automation, Inc. - CEO, President, Interim GM of Life Sciences & Director [3]

--------------------------------------------------------------------------------

Thank you, Mark, and good afternoon, everyone. We're glad to have you with us today. As we've already published preliminary results in a press release we issued on April 13th, I'll recap those results briefly and focus my remarks on some extra color at the segment level to give you some indication about how we see the current and near term business environment.

I'd like to start by discussing our priorities during this pandemic. First is the safety and wellbeing of our employees and their families as well as our partners including our suppliers and customers. Second, our ability to serve our customers that are deemed essential businesses with specific focus on any and all COVID-19 requests. And there have been many. And finally, the ongoing health of the company for the long term and actions we're taking to ensure that we emerge from this crisis stronger than ever.

With the exceptions of only a few brief work interruptions, all of our 20 plus factories, laboratories and repair centers were up and running throughout Q2 and all are currently operating. Of our approximately 3,300 global employees, about 1,800 have jobs that require them to be onsite. The rest of our employees are working from home. We are particularly proud of the way that each and every employee has embraced the new work practices that include social distancing, the diligent use of PPE, temperature screenings, staggered shifts and other practices which have allowed us to continue serving customers. All have adapted to this new work environment and we could not be more pleased with the resiliency of our operations during these turbulent times.

We consistently met our delivery commitments to customers as they struggled with their supply chains. And in many instances on the Life Sciences side, we stepped up to provide GENEWIZ, Sample Management and Informatic Services to customers who had either lost their regular services providers or who needed new services from us that came about because of the COVID-19 crisis. It's been energizing to bring even more capability to our customers and their need for our services underscores our purpose and mission.

Finally, we're building this company for the long term and our quarter to quarter and year to year revenue and earnings growth speaks to the momentum that we've generated. We've amassed an incredible technology and scientific portfolio, a global presence that allows us to deliver our world class capability to customers around the world, and we possess market positions in trusted brands that are the envy of our competitors. We've accomplished this through the energy and commitment of our global workforce. They know just how to ensure that we deliver on our long-term goals.

There is so much opportunity in front of us and it would be shortsighted of us to slow down now, especially since the capability we're building will be even more valuable in the future. For that reason, we intend to retain our team and fund their activities for technology development, new discovery, market capture, and customer support.

With each day that goes by, we're taking actions and making investments to emerge from the pandemic even stronger and more necessary to our customers. Our decision to continue these investments will have some impact on our earnings performance through the rest of this year, but we believe that it's absolutely the right action to take.

As companies and countries are contemplating how to reemerge from the pandemic, we have a definitive plan in place and a dedicated team that will continue to drive the momentum that we've established.

Now I'll report on Q2. Second quarter performance was strong with revenue of $220 million, up 11% year-over-year with the same 11% growth for each of our Semiconductor and Life Sciences segments. As I mentioned, for the most part our factories and laboratories were running throughout the quarter as we worked to meet customer demand, albeit it with many adjustments to mix because of both supply and demand changes throughout the quarter.

I'll begin with Life Sciences which delivered strong results with $95 million in revenue, up 4% sequentially with growth coming from both GENEWIZ and Sample Management. As each of these subsegments witnessed its own dynamics, I'll cover them separately starting with GENEWIZ.

Once again, GENEWIZ outperformed even our expectations, delivering a 25% year-over-year increase in revenue to $41 million. We were advantaged by our unique capability as both readers and writers of genes which allowed us to overcome some of the curveballs thrown our way. First, in early February when we announced our Q1 results, we told you that except for a team of scientists who remained onsite in support of urgent COVID-19 research, our Suzhou, China operations were basically shut down. It's in our Suzhou site where we perform the vast majority of our gene synthesis. Although we were bracing for what could have been a prolonged slowdown, China operations came back much faster than we'd imagined. By the end of February, more than 90% of our employees were back at work. And even without recovery in academia in China, demand from global customers was strong. In fact, despite the speedbump in February, the March quarter was a record for synthesis at just over $10 million.

Similarly, in next generation sequencing, we also had a record quarter with year-over-year growth of 46% and consistent 7% sequential growth, but with more volatility as the quarter progressed. We saw a normal pattern for NGS demand in the first two months of the quarter and then something of a spike in orders in the first half of March followed by two weeks of lower order volume. As we assess the NGS and synthesis businesses, we believe that much of the Q2 increase was the result of our normal customer capture. At the same time, it appears that some of the March burst came from researchers who no longer had capacity from their core laboratories or were facing reduced productivity from their existing suppliers while GENEWIZ remained at full capability and was eager to serve.

That said, order patterns for April have been steady but slightly lower in both synthesis and NGS but we have mixed signals as customer engagement for both synthesis and NGS projects remains quite active.

In Sanger sequencing, which is a high volume, overnight turns business where we perform millions of measurements for thousands of customers each quarter, revenue was steady for the first 10 weeks of the quarter. But when shelter in place orders closed many academic labs and caused a shutdown of nonessential research, we saw an abrupt reduction of more than 50% of our average daily volumes for the last two weeks of the quarter. And that level has persisted throughout most of April.

Though total Sanger revenue actually decreased slightly quarter-over-quarter, it was still up low single digits from Q2, one year ago. In Q3, we anticipate lower Sanger revenue until academic labs come back online and industry reaccelerates. And although we've seen average daily volumes increase during each of the past 4 weeks, we still remain below 50% of average. So at this point in the quarter, it would be too early to say that we have any concrete signs of a meaningful return to work.

In terms of overall GENEWIZ outlook, we expect business to be slightly down until academic researchers return to their benches and the activities that support clinical trials are back on the upswing. We don't have a prediction for when that will be, but we modeled a gradual return toward more normal volumes as we make our way through the rest of this quarter.

A difficult environment like the one we're in provides opportunities for companies that are prepared. In Q2, customers challenged us with hundreds of COVID-19 projects that gave us opportunities to demonstrate our incredible scientific acumen, round-the-clock collaboration, and fast turn, high quality results in support of their essential research. In addition, we took on many new urgent projects for first time customers. We believe that over the long run, it's this attention to solving customer issues that cement them to us and enabled GENEWIZ to add more than 200 new customers in the quarter.

Now I'll turn to Sample Management which even with all the disruption from coronavirus came in right on forecast I remind you that this year in Sample Management we have two areas of focus. A return to double digit revenue growth and sustainable gross margin improvement. And we're pleased with our progress against these goals. Even in this environment, Q2 was a very solid quarter. Revenue came in at $54 million, up 5% from Q1 and 3% year-over-year. Moreover, gross margin was up another 290 basis points from Q1. We're very encouraged by these results and it gives us confidence that this business is solidly on a path to be able to deliver on our expectations.

At the time we announced Q1 results, we knew two things. That the changes we had made to the organization structure and our focus on performance were set to deliver more growth and keep us on our trajectory for reacceleration of revenue in 2020, and that we were on track to deliver more profitability improvements.

That said, we also mentioned to you that we could foresee approximately $2 million of potential headwind from the coronavirus because of the inability of our field teams to complete system startups and perform revenue generating service on our equipment. Unfortunately, our customers obviously did not open for our employees and we did incur the headwinds that we had built into our forecast.

That said, there were many accomplishments in the quarter and I do want to highlight a few as they relate to trends in the business. Our cryogenics cold-chain products continue to make strong progress. Revenue topped $3 million in the quarter and we shipped B3C Cryo systems to 9 different customers. Six of those were repeat buyers. To date, 3/4 of our systems have been sold into cell and gene therapy applications and the momentum for these automated solutions continues to build.

In spite of the significant slowdown in clinical trial activity in March, Q2 Bio Storage activity generated our largest sample intake quarter since 2017, and we're encouraged by the reinvigoration of our customer capture activities. And in our consumables and instruments business lines, we made fast turn capital addition to respond to increased volume of consumables that will be used for COVID-19 tests as part of packages that we sell to diagnostics companies. This added capacity should allow us to increase revenue in Q3.

All-in, it was a very good quarter for Sample Management. Even with some COVID-19 related delays, revenue growth was right on track, profitability was ahead of schedule, and the result of our deliberate action is something that we'll build upon. The team is energized and active and we plan to come out of the COVID-19 days stronger than ever. What energizes us even more is the amount and level of large customer, large deal activity that's underway. During these days of no travel, our customer engagement activity has moved to the internet and deals that we've been working on for months are still being advanced. We are currently negotiating the final Ts and Cs on two large contracts and we have more multimillion dollar contracts in the pipeline. There opportunities speak to our capabilities and confidence to resume growth and profitability in this business.

On the semiconductor side, our performance in Q2 demonstrates the value of our product portfolio, and because of our close working relationship with our supply chain, we experienced only a small COVID-19 related revenue impact in the quarter which caused no impact to our customers. At $125 million in Q2, we established a new record high for quarterly semiconductor revenue and that's all the more remarkable because as an industry, we are still not back to our highs for semiconductor capital equipment spending. We attribute this outperformance to two factors. The strong high market share position of our Contamination Control Solutions business which satisfies a rapidly growing technology need, and continued design win and market share capture in our equipment automation products for OEM process equipment along with the steadily evolving advanced packaging market.

I'll give some specific color from our major Semiconductor business drivers, tool automation, advanced packaging and Contamination Control Solutions. Our automation products remained strong in the quarter with systems up approximately 10% and robots similar to last quarter's results. We had record bookings for our vacuum robots and vacuum systems, indicating demand remains very strong.

Sales to Chinese equipment manufacturers is picking up and this is a good indicator for both China fab activity and advanced packaging capability. We saw an uptick in advanced packaging in the quarter to just over $13 million or up 30% from Q1. This is still lower than one year ago, but it's the first sequential uptick in the last three quarters and in general a positive indicator. Based on order activity, we do have some indication that advanced packaging opportunities may be staring to percolate, especially in China.

Finally, I'll give a brief update on Contamination Control business which has been extremely strong as we delivered a record $45 million in revenue. The $45 million number is extremely significant for several reasons. First, we truly tested our supply chain and determined it to be very capable. In the first 2 quarters of 2020, we shipped as much revenue as in the last 3 quarters of 2019. And those were already healthy business levels.

Second, we met the demand for the expansion of the 5 Nanometer Foundry ramp on schedule and with very high quality. And finally, we continue to win additional business across a broad range of customers, device technologies that will serve us well as tier one foundry spending subsides.

Revenue in CCS will necessarily be lower in Q3 after two very strong back to back quarters, but still we expect healthy levels of more than $30 million in revenue which will be largely made up of a broader base of customers across different geographies and technology applications.

All-in, we're prepared for another strong quarter in our Semiconductor business. That said, we're also aware of some COVID-19 related supply chain issues that are slowing delivery of some parts. So far, we've been able to navigate through most of these issues, but it remains to be seen what the impact might be on actual demand from our customers. There's currently a lot of speculation as to the outlook for semiconductor processing equipment in 2020. Already our March quarter Semiconductor revenue was up 11% from one year ago and our Q2 Semiconductor book to bill was 1.2 for the quarter on a record revenue quarter. Depending upon June quarter capability of the global supply chain, our backlog and customer demand expectations would allow us to deliver yet another record quarter in June if we do not see any meaningful interruptions.

All-in, we had a very solid second quarter. We adjusted well as changes hit us and all companies. And we know that we'll need to rely on these same adaptive skills in the June quarter which may be even more uncertain. But already, we're well positioned and we're extremely confident in the long-term opportunities that we're diligently winning with all that we're investing today.

That concludes my formal remarks, and I'll turn the call now over to Lindon.

--------------------------------------------------------------------------------

Lindon G. Robertson, Brooks Automation, Inc. - Executive VP & CFO [4]

--------------------------------------------------------------------------------

Thank you, Steve. I'd like to refer your attention to the slides on our website, starting with Slide 3. Since Steve hit on these messages in his remarks, I will also be brief on what we see as the headlines of our performance. First, we had excellent momentum that has only modestly slowed by COVID-19 disruptions.

We have performed remarkably well with double digit year-over-year revenue growth in both segments and have established ourselves truly as a top reliable supplier in every market we serve.

Next, we expanded earnings substantially with continued performance enhancements in the Life Science segment. To put a finer point on it, gross margins in the Sample Management business are up nearly 600 basis points from a year ago. And third, we are well equipped for what lies ahead. Our liquidity is strong with $198 million of net cash on the balance sheet and healthy cash generation. To this point, our year-to-date cash flow from operations when you exclude the taxes paid on the sale of the semi cryo business, are $51 million. This a year-to-date improvement of $29 million over the prior year. The business is healthy and both sides are contributing growth, profit and cash flow.

Let's move onto Slide 4 to review the overall P&L. Let me first point you to the GAAP earnings and highlight what is different in that comparison. The growth of revenue and operating income is similar to that shown in the Non-GAAP profile on the right side. But what is different on the left side is in the tax line. If the first fiscal quarter, as guided under GAAP, we recognized a windfall tax benefit of approximately $6 million which is related to long term incentive stock units divested in the first quarter. That allowed deduction resulted in a net tax benefit of $3 million for the first fiscal quarter that in the second quarter is back to normal with the $3 million tax expense. The $6 million swing offsets the positive operating performance picture in the GAAP Profile.

In the Non-GAAP results, we apply this windfall to the projected tax rate and take it across the quarters of the fiscal year so that you can use the financials for a level performance indicator.

Continuing with the Non-GAAP performance on the right side, you can see the performance supported 48% year-to-year growth in earnings per share. Starting at the top, the revenue growth came similarly from each business with each growing 11% year to year. We saw a nice uptick in gross margins of 60 basis points sequentially, but Semiconductor gross margins remained approximately level from Q1 as expected. And the uptick was driven by Life Sciences improvement. On a year-over-year basis, the dynamics are also similar with improvement in Life Sciences and a bit softer margins in semiconductor. But all-in, gross margins continue to make progress and contribute to the bottom line.

Operating expenses during the quarter were up. On a sequential basis, the increase was in R&D for our Semiconductor business. Our engineering team has been kept busy throughout the COVID-19 environment, committed to advancing the projects with customers. On a year-over-year basis, operating expense was $7 million higher, driven by both R&D and SG&A. In the SG&A line, the growth was driven primarily around investments in Life Sciences including our IT transition to a single cloud based ERP platform, GENEWIZ growth, and some additional structure from our recent acquisition of RURO Software.

While we are spending some extra to keep our team in a safe environment and onboard with us through the COVID crisis, we anticipate reductions in travel expenses and G&A which will result in lower operating expense by approximately $1 million to $2 million in the third quarter. You can see operating margin expansion. Combining the growth with the margin expansion, you can also see Non-GAAP net income grew 51% year-over-year and expanded 11% sequentially.

Moving to below the operating income line, net interest expense was $600,000, lower by about $7 million compared with last year when we were carrying debt associated with the GENEWIZ acquisition. The non-GAAP tax rate for the quarter came in at about 23%, very consistent with our expectation of 21% to 25% for the year.

Let's turn now over to Slide 5 to discuss the segment results, starting with Life Sciences. In the second quarter, Life Sciences revenue grew 11% to $95 million compared with the second quarter last year. On an organic basis, Life Sciences grew 11% as well. This quarter was the first full year-over-year comparison which includes a full quarter of GENEWIZ revenue since the acquisition of the business in November of 2018. GENEWIZ had a strong second quarter with a revenue of $41 million, growing 25% from last year despite the impacts of COVID-19 as Steve addressed. As a reminder, our GENEWIZ China operations were largely closed down and observed strict quarantine restrictions from that Chinese New Year through February 10th. The exception to that were the labs from which GENEWIZ provided gene synthesis support for COVID-19 research customers. We estimated that the shutdown had an impact of approximately $2 million in the quarter. We are currently fully operational and demand from the China market has largely returned.

Sample Management provided 3% organic growth during the quarter in line with our expectation when we started the quarter. We had described and we did see about $2 million headwind from COVID-19 in the large store systems and post warranty services. This was due to some delays in an onsite installation and general lack of access to customer sites. But there were bright spots in Sample Management as well. Year-over-year growth was driven by cryo which more than doubled, and more substantively, Bio Storage services grew 7%. We have been very encouraged by the continued significant engagements and wins by the teams in the large storage business and in Bio Storage during this environment, fueling the path to return to double digit growth.

In addition, during the second quarter we acquired the Life Science Informatics Software firm RURO. RURO provides cloud-based software solutions to manage the laboratory workflow and bio sample data for a broad range of customers in the biotech, healthcare and pharmaceutical sectors. The business contributed approximately half a million of revenue in the time that we've owned them since mid-February.

As we announced in a March press release effective April 1st, we reorganized our Life Sciences business. We've combined the Bio Storage services with GENEWIZ, leveraging the common lab services and sample handling capabilities. This business combined is now $64 million of this quarter's $95 million business and showed year-to-year growth on that basis of 17%.

The remaining portion of the segment of Life Sciences is the Life Sciences products which was about $31 million and was up 1% year-over-year. If we had avoided the negative impact of the COVID-19 constraints, we estimate that the Life Science Products business would have grown about 4%.

Another bright spot in the quarter was on the gross margin line. The segment improved nicely in the second quarter up to 45.8%, up 330 basis points compared with last year. The year-over-year improvement was driven by the performance in Sample Management. In fact, we had improvement on every area of the business including our large TwinBank's store systems and services, the cryo systems, the consumables and instruments, and the Bio Storage services. This is driven by the performance improvements and cost reductions and the improved price management that's been implemented.

The growth of the segment and gross margin expansion covered the increased operating expense and drove 260 basis points of incremental operating margin year-over-year. The leverage of this business model and growth is fully evident on this page.

As we look into the third quarter, we are more cautious due to the continued and varied impacts of COVID-19. As Steve described, we've seen inside GENEWIZ sustained demand in synthesis, some volatility in the next generation sequencing, and a lower run rate from Sanger sequencing. Most notable to use is that continued absence of the academic research institutions and we have seen only a portion of the commercial teams return to full active status. And in Sample Management, it is unclear when customer sites will fully open around the world, limiting our access for installations and services. So at this point, we're expecting Life Sciences to deliver revenue in the range of $85 million to $91 million which is about 5% to 10% lower quarter-to-quarter.

Let's turn over to Slide 6 to review our Semiconductor business. Semiconductor Solutions revenue was $125 million for the second quarter, an increase of 5% sequentially and 11% year-over-year. If you were to look into the details of the quarter-to-quarter, you would see an uptick in the systems business which we ship primarily to tier two OEMs. I would highlight that the strength in that line in is the atmospheric systems as we expected. We do expect to see more vacuum systems coming in the second half which should assist gross margin.

The real story in the revenue line however is the strength of the Contamination Control Solutions which indeed ships to end user fabs. As referenced, these are record quarters for us in CCS and we continue to see expansion of qualifications and orders across many fabs. The rest of the Semiconductor story is in robots. While it is stable quarter-to-quarter, it is significantly higher year-over-year and our tier one OEM customers continue to call for additional output as we head into our second half.

It may appear we face no challenges in the second quarter, but in fact, the accomplishment reflects much diligence to coordinate supply availability, factory production and of course customer needs. We estimate that the negative impact to COVID-19 on revenue during the quarter for Semiconductor was approximately $5 million due to supply chain and the services challenges. On the positive side, these are delayed, not lost opportunities and due to the coordination efforts, our customers were not surprised nor disappointed by us.

Gross margins in Semi were similar to the prior quarter at about 40% and operating margins improved by 70 basis points. As mix improves in the second half, we expect gross margins to strengthen and if the market holds, growth will bring operating margins back upward on the leverage of the model.

Similar to the Life Science business, we're cautious about the outlook for the third quarter. We expect our supply chain will continue to face some issues. We also are sensitive that the broader supply chain of our customers aside from us affects the end user's timing for when they need our products. Finally, we know the impact of COVID-19 on the end markets can change rapidly. We expect our semiconductor business to deliver revenue in the range of $115 million to $124 million. This is approximately flat to lower -- I'm sorry, flat to down 8% quarter-to-quarter.

Let's turn now over to Slide 7 for a summary of our cash flow over the quarter. We generated $26 million of adjusted operating cash flow during the quarter. This excludes $92 million of income tax payments associated with a gain of the 2019 sale of our semiconductor cryo business. We also used approximately $16 million of cash for the acquisition of RURO as mentioned previously.

Our CapEx amounted to $12 million for the quarter, driven primarily by investments in operations and it includes approximately $1 million for the new GENEWIZ operation facility in Suzhou, China. Total uses of cash during the quarter totaled $105 million, and the change in net cash and equivalents during the quarter brings our cash, restricted cash and cash equivalents balance down to $249 million. The highlight here is the cash capability of the business we have built with GENEWIZ and subsequent to the divestiture of the semi cryo business. Year-to-date, as I said before, our operating cash flow when you exclude the tax on the gain in the sale, was $51 million or an increase of $29 million year-over-year.

On Slide 8, you will see a summary of the balance sheet. You can see at the top of the March 31st column we now carry $249 million in cash and marketable securities. With $51 million of debt, we have $198 million of net cash for operations and investments. This strong position provides us the fuel to invest for growth and gives us the confidence we will weather these uncertain times, and customers and our employees the confidence that we will sustain our investments.

Let's turn now to the summary on Slide 9. Fundamentals of the business are intact and we've gained customers and market share during these times. We have extended our leadership and continue preparing ourselves to be ready to accelerate when the recovery of the market. The balance sheet is strong, provides us the fuel for the journey and the strategic flexibility. We have seen growth momentum in each business. In Semiconductor we saw strong orders and have healthy backlog. But we also know the WFE CapEx environment comes down to the path which the chip makers decide to take. And in this time in particular, the OEM customers depend on a broad supply chain that is vulnerable.

Our Life Sciences business continues to win new business. The active markets of pharma, biotech and clinical continue to engage on improving their infrastructure with our capabilities and to request our support for the COVID research that they have stepped up to do themselves. So meanwhile, the academic research institutions have not returned to work yet and the timing of that return is uncertain and varied across the regions. So we find ourselves with unusually mixed signals. Good customer demand momentum, but uncertain market continuity in the near term. We have solid backlog but uncertain access to some customer locations. But there is one aspect that is very clear to us. We have the momentum with customers and the opportunity to delight them. If we keep that momentum with us, we will maintain our resources and be ready for the ramp as markets do fully return. In the short term, we are carrying some costs. We have some elements of our business less active during this time, but we're going to keep the team employed. We are providing premium pay for onsite labor, ensuring the PPE and clean facilities make a safe environment and expediting shipments to satisfy stressed delivery schedules. We will carry some so this cost in the short term and we will win additional customers as we are there for them throughout and we will be prepared for the full recovery ramp as the market returns to working order.

Let's cover that guidance for the third fiscal quarter of 2020. Revenue is expected to be in the range of $200 million to $215 million. Adjusted EBITDA is anticipated to be $26 million to $34 million and non-GAAP diluted earnings per share to be $0.16 to $0.24 per share. GAAP will be in the range of $0.04 to $0.12. For Life Sciences we factored in a return of the markets in the June month. This now concludes our prepared remarks, and I'll turn the call back over to Malaika, the Operator, to take questions from the line.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first phone question is from the line of Patrick Ho with Stifel. Please go ahead, your line is open.

--------------------------------------------------------------------------------

J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [2]

--------------------------------------------------------------------------------

Thank you very much and hope everyone is well. And congrats on a really nice quarter in these challenging circumstances. Steve, maybe first off, in terms of the disruptions and the volatilities you've been seeing, can you give a little bit of color on your end how you were able to manage a very fluid environment and ensure that your top tier customers got what they needed? What were some of the steps you took? How did the business continuity plan work? If you could just give a little bit of color on that first.

--------------------------------------------------------------------------------

Stephen S. Schwartz, Brooks Automation, Inc. - CEO, President, Interim GM of Life Sciences & Director [3]

--------------------------------------------------------------------------------

Sure, Patrick, and thanks for the question on this. Specifically, on the Semi side, we give a lot of credit to the large OEM customers. They give us a good look at the business. And they adjust it quite frequently, so we're able to get out in front of the supply chain. And then our team managed the supply base extremely well. I think this is something over the past years that's become really fluid. When we get a signal from our tier one OEMs, we're able to transmit that quickly to our suppliers to get them prepared and I think the team managed it really well. It wasn't without problems for sure, but everybody knew how to accelerate and to get the job done. And Patrick, inside the company, everybody knows that deliveries to the customers are top priority, so if we go overtime, we spend. If we do something to get shipments there, we do it. And so I think it's a successful model that played out through the COVID period. And I think the business continuity plans that we have in place, we kicked them into action and I think they played out extremely well. I don't know that anybody could have anticipated the magnitude of what everybody was going to be faced with. But I think the team responded well. We're functioning completely differently just even two weeks into the shutdown period. Two weeks into the shutdown period we were operating with the same fluidity, but in a really different mode. So in general, the things that should have happened did. And we continue to manage going forward the supply base. There are air pockets we're finding coming from India, from Malaysia that we've been trying to work through now for the past 5 weeks. I think we're doing very well, but when you hear uncertainty from everybody in and around the supply chain, I think we're all dealing with the same kinds of things. But I do believe the team is in front of it and we seem to be weathering it pretty well.

--------------------------------------------------------------------------------

J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [4]

--------------------------------------------------------------------------------

View post:
Edited Transcript of BRKS earnings conference call or presentation 30-Apr-20 8:30pm GMT - Yahoo Finance

In this report, the global Cancer Gene Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Cancer Gene Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Cancer Gene Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Cancer Gene Therapy market to assist our clients arrive at beneficial business decisions.

The Cancer Gene Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cancer Gene Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/2988

Resourceful insights enclosed in the report:

The major players profiled in this Cancer Gene Therapy market report include:

Some of the major companies operating in the global cancer gene therapy market are Cell Genesys, Advantagene, GenVec, BioCancell, Celgene and Epeius Biotechnologies. Other leading players in cancer gene therapy market include Introgen Therapeutics, ZIOPHARM Oncology, MultiVir and Shenzhen SiBiono GeneTech

Key points covered in the report

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/2988

The market report addresses the following queries related to the Cancer Gene Therapy market:

The study objectives of Cancer Gene Therapy Market Report are:

To analyze and research the Cancer Gene Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cancer Gene Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cancer Gene Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Cancer Gene Therapy market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/2988

View original post here:
Coronavirus (COVID-19) Business Impact Mounting Prices of Coupled With Onset of Cost-effective Alternatives to Fuel the Growth of the Cancer Gene...

This essay first appeared on The MIT Reader on April 20, 2020

Across the world, many of us are imagining a possible rendezvous with Death. Some are turning to common addictions, such as alcohol and drugs. A study last week found that nearly 40 percent of remote-working New Yorkers are drinking while working, and one in five are stockpiling booze. Others arecoming together, figuratively speaking, to help those in great need. Still others are circling their wagons and loading up on more guns and ammo.

When circumstances jolt us from our routines, we grow unsettled and anxious. Some of us manage to resetsomehow grasping that business is not as usual, that time could be short. We manage to ask, What really matters now? For many, the answer is, help others.

Empathy and altruism are primordial human traits. When we wandered as foragers for 200,000 years, resources were iffy. So we smoothed out potentially fatal fluctuations by elaborating our instinct to share. But we didnt invent these circuits: A free rat, encountering a trapped rat, will make an effort to release it. And a rat, pulling a lever to obtain food pellets, will choose the lever that doesnt shock a stranger rat, even when that lever delivers two times less food. Thus neural circuits for empathy and altruism have likely been around since our last shared ancestor with rodentsnearly 100 million years.

Certain aspects of the neurobiology are clear. When we share our own resources to help a neighbor, they receive, besides practical aid, a pulse of dopamine from a core neural circuit that rewards every unexpected positive event. This neurochemical pulse evokes a pulse of good feeling, a momentary relief from seeking. Critically, this same circuit also rewards thegiver, thereby encouraging us to repeat that behavior in the iffy times to come. Living as we do now, this instinct to share has been little exercised. Multitudes in our cities have been lacking food and shelter, but they have been discounted as somehow undeserving. Otherwise, we would not have turned away for so long.

But now, suddenly,weare the needy, many desperate for sustenance and comfort. We encounter and welcome empathy and sharing, not just food and soap, but even our neighbors voices serenading us from their balconies. We recall such empathic, altruistic behaviors from earlier crises, such as urban blackouts, hurricanes, and floods. These behaviors provide dopamine beyond the givers and the receiversto all who share their emotionally uplifting stories. But what are we to make of the wagon-circlers? Whatisit with those people for whom sharing is neither a value nor a pleasure? They are numerous, so we should try to understand rather than write them off.

Empathy is a complex trait, like courage, or height. Traits are often partially inherited through our geneswith the degree of expression involving many genes with small effects. For height, for example, most people inherit roughly equal numbers of genes for short and for tall. Consequently, on the bell curve for height, they occupy the middlethey are average. Those who inherit more genes for short tend to be shorter than average, and those who inherit the opposite, more genes for tall, tend to be taller than average. When tall parents transmit abundant tall genes to their offspring, the occasional child may inherit 200 more genes for tall. If this child is male and well-fed, he may grow to seven and a half feet and play professional basketball. On the bell curve for height, he is far out on the tail.

Empathy has a substantial genetic contribution, about half as much as height, a group of researchers found in 2018. Inevitably, some individuals inherit more pro-empathy genes than average. Moreover, since they are likely to be born from empathic parents, such children will also witness empathic behaviors and be rewarded for performing them. Thus, learning and family values reinforce the pro-social neural circuitry. Such individuals are likely to become professional caregivers.

Inevitably, as well, some individuals inherit fewer pro-empathy genes than average and tend to feel less empathy. Moreover, since low empathy children are likely born from low empathy parents, they are less likely to witness empathic behaviors or be rewarded for performing them. An analogy would be short parents spawning short children and then starving them.

But why, since we evolved brain circuits for empathy, should any of us be deficient for this trait? Why cant we all be above average? Apparently, because our species success gains from individuals on both sides of the bell curve. Obviously, we benefit from individuals with high empathysharers and carers. But we also benefit from high functioning individuals with low empathy. Three thousand years ago King David was an awesome leader even as he coldheartedly sent his lovers husband to die in battle.

Low empathy individualslets face ithave appeal, which is why they succeed as politicians and media stars. They appeal especially to those of below-average empathy, that is, half of the population. For those of low empathy it can be thrilling to watch a leader without scruples live so close to who he really is. Unconstrained by others needs or feelings, he seems free. Whereas, those imbued with strong empathy are condemned to search continually for a sweet spot between the call of their own needs and those of others. Ironically, the empathizers may spend years in therapy trying to liberate their inner sociopath.

Now, in the shadow of COVID, neuroscience and genetics reminds us that for every human trait, there is a distribution. As we proceed to our empathic sweet spots, we have no choice but to accept it.

Link:
COVID-19 and the Harsh Reality of Empathy Distribution - Scientific American

Safety WarningDo Not Exceed Recommended Dose.When using nutritional supplements, please inform your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.This product is labelled to United States standards and may differ from similar products sold elsewhere in its ingredients, labeling and allergen warningsIndicationsINDICATIONS= Used to supplement ones diet, exercise routine, sports, weightlifting, cycling, running, strength training, conditioning, football, soccer, rugby, basketball, tennis, general well being! To increase ones strength and endurance in their workouts, exercise program or during any sport related activities.Legal DisclaimerWARNING: Consuming this product can expose you to chemicals including lead, which are known to the State of California to cause cancer. For more information go to http://www.P65Warnings.ca.gov/food.

Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.

Continue reading here:
Amazon.com: Life Extension Mega Green Tea Extract (Lightly ...

PC is not grumpy!

Editor:

This letter is in response to Sara Howells comments about PebbleCreek having an age discrimination problem. I have lived in PebbleCreek for almost seven years and have never had the problems she said she experienced.

First, and most importantly, PebbleCreek is a 55-and-older community. There is a certain amount of under-55 people allowed within the community, but most of the population is, yes, over 55! I dont know how Sara was ever allowed to rent in PebbleCreek being 37 years old unless it was done under the table! Why would she ever want to rent in this community being the age that she is? And Sara knew it was a 55-and-over community prior to moving in.

There must have been other circumstances for her being scolded for driving 21 mph in a 25 mph zone. Many people will drive that slowly and nothing is said to them. People even drive over the speed limit and do not get scolded unless caught by the patrol. So, the comment seems very jaded to me.

As far as her being aggressively screamed at for walking in an area that Im not supposed to be walking in, I would presume that to be the golf course. The person was probably playing golf, was quite a distance from her and yelled loud enough for her to hear and stop walking on the golf course. A 37-year-old, if it was the golf course, should have lived enough to know you never take a walk on a golf course, unless you are playing golf. If everyone did it the fairways would be damaged, etc. Her complaints have nothing to do with her being under 40. She was not following the rules of the community. Even a renter has an obligation to know and follow the community rules.

Renting to someone who is 37 is not stopping a house from being foreclosed upon. Most of the houses in PebbleCreek are paid for. The community has no problem with a person who pays her bills (we all do) or serves the community as an educator (there are many retired educators in the community myself included).

You were not preyed upon by people in this community. You were not following the rules. There are some grumpy individuals in the community, but the great majority of people are absolutely delightful! Before you criticize PebbleCreek as a community, get to know some people. You may change your mind. And if you continue to be unhappy in this age-restricted community, maybe you should find a nonage-restricted community to live in.

Barb Roberts

Goodyear

Review the rules

Editor:

This person was called out because of her behavior, not because of her age. There a many published rules and regulations in PebbleCreek that are designed to protect property and public safety. It is every residents responsibility to review these and adhere to them.

My sense is that the resident was driving well beyond the posted 25 mph speed limit when she was scolded. Did she brake quickly and then notice her speed? Was she distracted? Many PebbleCreek residents are in their 70s and 80s and do not have the quick reaction time of someone in their 30s.

Also, was she walking along the cart path on one of the golf courses when she was screamed at? For everyones safety, this is not allowed. This rule is in the HOA guidelines. Warning signs are not necessary or required. This is a golf course, not a carton of cigarettes. My sense is that this resident would be the first to sue the HOA if she were hit by a golf ball.

The vast majority of residents of PebbleCreek are here because of the outstanding population of great people from across the United States and Canada. We enjoy each other, our children and grandchildren when they visit us; the many activities provided to us; and living in a safe and vibrant community that is part of Goodyear.

We do not prey on those under 40.

Michael Quinn

Goodyear

Dont be so callous

Editor:

I just finished reading Charles Peabodys letter to the editor in the April 8 issue. What an astoundingly inaccurate piece of nonsense. Factually incorrect and appallingly callous.

Contrary to the claptrap on Facebook, COVID-19 is not a cold; it is a serious respiratory illness. According to his letter, a 1% serious illness rate is not a problem because most of the remaining 1% are susceptible to just about any medical issue due to their advanced age and preexisting conditions. That is factually incorrect. It is affecting people of all ages and is responsible for deaths in all age groups and physical conditions, although those with compromised immune systems and underlying disorders are more likely to die.

That said, Mr. Peabody seems to think thats acceptable if we can get people back to work and children back in school. He also said, Giving a couple thousand people their 87th Christmas is not much comfort to tens of millions of breadwinners who wont be able to afford holiday gifts Really? Hes worried about Christmas presents more than peoples lives? And this doozy: Maybe these elderly survivors will read one or two more books before they pass on It sounds like hed support just rounding up all us geezers and sending us to a camp to die and be done with us.

Its time for some real facts, as opposed to the alternative facts being spewed by the right and found on Facebook and other unverifiable social media sites. As of the morning of April 9, the mortality rate among infected people in the United States was about 3.53%. The population of the United States is about 330 million. That extrapolates to about 11.6 million deaths if everyone in the country is exposed to it. Even if we assume Mr. Peabodys 1% number is correct (which it isnt) that would still be 3.3 million deaths. I cant imagine any civilized society finding this acceptable for any reason, much less trading those lives for money. Remember, economies recover, but dead people dont.

Now some questions for Mr. Peabody and others who share his misguided opinions on this: Which elderly people in your family are you OK with dying for your convenience? What age would you arbitrarily establish as becoming officially expendable to the greater needs of the younger generation? How old are you and when will you be ready to consider yourself obsolete and redundant and make the sacrifice for the younger generation to make some money?

Lastly, his letter stated: Indeed COVID-19 itself is not virulent enough to have a lasting physical impact on our society. Thats not being an optimist; thats sticking your head in the sand.

Jude Clark

Buckeye

Scary philosophy

Editor:

Mr. Peabody carefully avoids the words death panel, but what other social function would fulfill his fantasy of considering the hypothetical benefits of giving aged and sickly people a slight life extension versus more comfort to breadwinners? He even tosses off the suggested age of 86 as the right age to sacrifice oneself to the economy. Well, that hits a little close to home for this family. Mr. Peabodys factual errors speak for themselves, but his philosophy should terrify his neighbors. I hope he keeps his death wishes away from our loved ones.

Jason Bentley

Litchfield Park

We are not one

Editor:

I love my country. I love the patriotic strains of the popular hymns America the Beautiful and others. I love the sense of unity assumed within the designation of American. When my kids were young, they asked me why I repeatedly viewed old WWII documentaries. Do you enjoy human suffering, dad? I replied no, but that I did enjoy the sense of unity among Americans at that time of stress and conflict. We were one.

Today we are not one, not just because we disagree in political opinion, but because we disagree on the cause and purpose of America; this is beyond disheartening. Hatred and self-loathing have since permeated our ranks in a most disagreeable manner. Hatred is corrosive, it clouds sound judgment, and prohibits ones ability to be objective and rational because it is emotionally driven.

Now, at this unprecedented time of pandemic displacement and uncertainty, it is refreshing that recent polls indicate a majority of Americans approve of the presidents efforts to address COVID-19 and economic issues since we all want America to succeed. There are some who seemingly do not want America to succeed. Rather than help and support, they impede and scorn, clearly driven by ugly hatred which blinds their eyes to fact, logic, liberty, free enterprise and patriotism. These hate-filled and ignorant comments are largely directed toward the president and his supporters. Supreme court justices have been threatened. The president is now being accused of crimes against humanity and second-degree murder,

Alec Baldwin going so far as to say, If you vote for Trump again you are mentally ill. Really? Can you imagine the backlash if a conservative had made such outlandish statements? How on Earth are we supposed to take the extreme left seriously? The ongoing leftist effort to overturn the 2016 election has morphed from ridiculous, to shameless unabashed absurdity, to the surreal because of personal hatred; if this president discovered a cure for cancer the left would villainize him and call for an inquiry. Friends, to disagree is American. But to hate, or support those that hate, is neither constructive nor respectable.

Jason Russell

Goodyear

Original post:
Lettters to the Editor | Opinion - westvalleyview.com

Complete study of the global Milk Thistle Health Tonic, market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Milk Thistle Health Tonic, industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Milk Thistle Health Tonic, production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Milk Thistle Health Tonic, market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Milk Thistle Health Tonic

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1696541/covid-19-impact-on-global-milk-thistle-health-tonic-market

Segmental Analysis

The report has classified the global Milk Thistle Health Tonic, industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Milk Thistle Health Tonic, manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Milk Thistle Health Tonic, industry.

Global Milk Thistle Health Tonic, Market Segment By Type:

, Tablets, Capsules, Others Milk Thistle Health Tonic

Global Milk Thistle Health Tonic, Market Segment By Application:

Dietary Supplement, Health Food

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Milk Thistle Health Tonic, industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Milk Thistle Health Tonic, market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold Milk Thistle Health Tonic

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3900): https://www.qyresearch.com/settlement/pre/80683c606bc4072691a6b6f3cf0d15ff,0,1,covid-19-impact-on-global-milk-thistle-health-tonic-market

TOC

1 Study Coverage1.1 Milk Thistle Health Tonic Product Introduction1.2 Market Segments1.3 Key Milk Thistle Health Tonic Manufacturers Covered: Ranking by Revenue1.4 Covid-19 Implications on Market by Type1.4.1 Global Milk Thistle Health Tonic Market Size Growth Rate by Type1.4.2 Tablets1.4.3 Capsules1.4.4 Others1.5 Covid-19 Implications on Market by Application1.5.1 Global Milk Thistle Health Tonic Market Size Growth Rate by Application1.5.2 Dietary Supplement1.5.3 Health Food1.6 Coronavirus Disease 2019 (Covid-19): Milk Thistle Health Tonic Industry Impact1.6.1 How the Covid-19 is Affecting the Milk Thistle Health Tonic Industry1.6.1.1 Milk Thistle Health Tonic Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Milk Thistle Health Tonic Potential Opportunities in the COVID-19 Landscape1.6.3 Covid-19 Impact on Key Regions1.6.4 Proposal for Milk Thistle Health Tonic Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary2.1 Covid-19 Implications on Global Milk Thistle Health Tonic Market Size, Estimates and Forecasts2.1.1 Global Milk Thistle Health Tonic Revenue 2015-20262.1.2 Global Milk Thistle Health Tonic Sales 2015-20262.2 Covid-19 Implications on Global Milk Thistle Health Tonic, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Milk Thistle Health Tonic Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Milk Thistle Health Tonic Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Covid-19 Implications on Global Milk Thistle Health Tonic Competitor Landscape by Players3.1 Milk Thistle Health Tonic Sales by Manufacturers3.1.1 Milk Thistle Health Tonic Sales by Manufacturers (2015-2020)3.1.2 Milk Thistle Health Tonic Sales Market Share by Manufacturers (2015-2020)3.2 Milk Thistle Health Tonic Revenue by Manufacturers3.2.1 Milk Thistle Health Tonic Revenue by Manufacturers (2015-2020)3.2.2 Milk Thistle Health Tonic Revenue Share by Manufacturers (2015-2020)3.2.3 Global Milk Thistle Health Tonic Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Milk Thistle Health Tonic Revenue in 20193.2.5 Global Milk Thistle Health Tonic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Milk Thistle Health Tonic Price by Manufacturers3.4 Milk Thistle Health Tonic Manufacturing Base Distribution, Product Types3.4.1 Milk Thistle Health Tonic Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Milk Thistle Health Tonic Product Type3.4.3 Date of International Manufacturers Enter into Milk Thistle Health Tonic Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Covid-19 Implications on Market Size by Type (2015-2026)4.1 Global Milk Thistle Health Tonic Market Size by Type (2015-2020)4.1.1 Global Milk Thistle Health Tonic Sales by Type (2015-2020)4.1.2 Global Milk Thistle Health Tonic Revenue by Type (2015-2020)4.1.3 Milk Thistle Health Tonic Average Selling Price (ASP) by Type (2015-2026)4.2 Global Milk Thistle Health Tonic Market Size Forecast by Type (2021-2026)4.2.1 Global Milk Thistle Health Tonic Sales Forecast by Type (2021-2026)4.2.2 Global Milk Thistle Health Tonic Revenue Forecast by Type (2021-2026)4.2.3 Milk Thistle Health Tonic Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Milk Thistle Health Tonic Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Covid-19 Implications on Market Size by Application (2015-2026)5.1 Global Milk Thistle Health Tonic Market Size by Application (2015-2020)5.1.1 Global Milk Thistle Health Tonic Sales by Application (2015-2020)5.1.2 Global Milk Thistle Health Tonic Revenue by Application (2015-2020)5.1.3 Milk Thistle Health Tonic Price by Application (2015-2020)5.2 Milk Thistle Health Tonic Market Size Forecast by Application (2021-2026)5.2.1 Global Milk Thistle Health Tonic Sales Forecast by Application (2021-2026)5.2.2 Global Milk Thistle Health Tonic Revenue Forecast by Application (2021-2026)5.2.3 Global Milk Thistle Health Tonic Price Forecast by Application (2021-2026) 6 North America6.1 North America Milk Thistle Health Tonic by Country6.1.1 North America Milk Thistle Health Tonic Sales by Country6.1.2 North America Milk Thistle Health Tonic Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Milk Thistle Health Tonic Market Facts & Figures by Type6.3 North America Milk Thistle Health Tonic Market Facts & Figures by Application 7 Europe7.1 Europe Milk Thistle Health Tonic by Country7.1.1 Europe Milk Thistle Health Tonic Sales by Country7.1.2 Europe Milk Thistle Health Tonic Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Milk Thistle Health Tonic Market Facts & Figures by Type7.3 Europe Milk Thistle Health Tonic Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Milk Thistle Health Tonic by Region8.1.1 Asia Pacific Milk Thistle Health Tonic Sales by Region8.1.2 Asia Pacific Milk Thistle Health Tonic Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Milk Thistle Health Tonic Market Facts & Figures by Type8.3 Asia Pacific Milk Thistle Health Tonic Market Facts & Figures by Application 9 Latin America9.1 Latin America Milk Thistle Health Tonic by Country9.1.1 Latin America Milk Thistle Health Tonic Sales by Country9.1.2 Latin America Milk Thistle Health Tonic Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Milk Thistle Health Tonic Market Facts & Figures by Type9.3 Central & South America Milk Thistle Health Tonic Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Milk Thistle Health Tonic by Country10.1.1 Middle East and Africa Milk Thistle Health Tonic Sales by Country10.1.2 Middle East and Africa Milk Thistle Health Tonic Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Milk Thistle Health Tonic Market Facts & Figures by Type10.3 Middle East and Africa Milk Thistle Health Tonic Market Facts & Figures by Application 11 Company Profiles11.1 Health Genesis11.1.1 Health Genesis Corporation Information11.1.2 Health Genesis Description, Business Overview and Total Revenue11.1.3 Health Genesis Sales, Revenue and Gross Margin (2015-2020)11.1.4 Health Genesis Milk Thistle Health Tonic Products Offered11.1.5 Health Genesis Recent Development11.2 Pure Encapsulations11.2.1 Pure Encapsulations Corporation Information11.2.2 Pure Encapsulations Description, Business Overview and Total Revenue11.2.3 Pure Encapsulations Sales, Revenue and Gross Margin (2015-2020)11.2.4 Pure Encapsulations Milk Thistle Health Tonic Products Offered11.2.5 Pure Encapsulations Recent Development11.3 Regis11.3.1 Regis Corporation Information11.3.2 Regis Description, Business Overview and Total Revenue11.3.3 Regis Sales, Revenue and Gross Margin (2015-2020)11.3.4 Regis Milk Thistle Health Tonic Products Offered11.3.5 Regis Recent Development11.4 Solgar11.4.1 Solgar Corporation Information11.4.2 Solgar Description, Business Overview and Total Revenue11.4.3 Solgar Sales, Revenue and Gross Margin (2015-2020)11.4.4 Solgar Milk Thistle Health Tonic Products Offered11.4.5 Solgar Recent Development11.5 Aksuvital11.5.1 Aksuvital Corporation Information11.5.2 Aksuvital Description, Business Overview and Total Revenue11.5.3 Aksuvital Sales, Revenue and Gross Margin (2015-2020)11.5.4 Aksuvital Milk Thistle Health Tonic Products Offered11.5.5 Aksuvital Recent Development11.6 BEC11.6.1 BEC Corporation Information11.6.2 BEC Description, Business Overview and Total Revenue11.6.3 BEC Sales, Revenue and Gross Margin (2015-2020)11.6.4 BEC Milk Thistle Health Tonic Products Offered11.6.5 BEC Recent Development11.7 NC11.7.1 NC Corporation Information11.7.2 NC Description, Business Overview and Total Revenue11.7.3 NC Sales, Revenue and Gross Margin (2015-2020)11.7.4 NC Milk Thistle Health Tonic Products Offered11.7.5 NC Recent Development11.8 Life Extension11.8.1 Life Extension Corporation Information11.8.2 Life Extension Description, Business Overview and Total Revenue11.8.3 Life Extension Sales, Revenue and Gross Margin (2015-2020)11.8.4 Life Extension Milk Thistle Health Tonic Products Offered11.8.5 Life Extension Recent Development11.9 Swisse11.9.1 Swisse Corporation Information11.9.2 Swisse Description, Business Overview and Total Revenue11.9.3 Swisse Sales, Revenue and Gross Margin (2015-2020)11.9.4 Swisse Milk Thistle Health Tonic Products Offered11.9.5 Swisse Recent Development11.10 HerbsofGold11.10.1 HerbsofGold Corporation Information11.10.2 HerbsofGold Description, Business Overview and Total Revenue11.10.3 HerbsofGold Sales, Revenue and Gross Margin (2015-2020)11.10.4 HerbsofGold Milk Thistle Health Tonic Products Offered11.10.5 HerbsofGold Recent Development11.1 Health Genesis11.1.1 Health Genesis Corporation Information11.1.2 Health Genesis Description, Business Overview and Total Revenue11.1.3 Health Genesis Sales, Revenue and Gross Margin (2015-2020)11.1.4 Health Genesis Milk Thistle Health Tonic Products Offered11.1.5 Health Genesis Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Milk Thistle Health Tonic Market Estimates and Projections by Region12.1.1 Global Milk Thistle Health Tonic Sales Forecast by Regions 2021-202612.1.2 Global Milk Thistle Health Tonic Revenue Forecast by Regions 2021-202612.2 North America Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.2.1 North America: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.2.2 North America: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.2.3 North America: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.3 Europe Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.3.1 Europe: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.3.2 Europe: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.3.3 Europe: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.4.2 Asia Pacific: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Milk Thistle Health Tonic Market Size Forecast by Region (2021-2026)12.5 Latin America Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.5.1 Latin America: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.5.2 Latin America: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.5.3 Latin America: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Milk Thistle Health Tonic Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Milk Thistle Health Tonic Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Milk Thistle Health Tonic Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Milk Thistle Health Tonic Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Milk Thistle Health Tonic Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis14.2 Milk Thistle Health Tonic Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
Milk Thistle Health Tonic, Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| Health Genesis, Pure Encapsulations,...

Complete study of the global Covid-19 Impact on Milk Thistle Health Tonic market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Covid-19 Impact on Milk Thistle Health Tonic industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Covid-19 Impact on Milk Thistle Health Tonic production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Covid-19 Impact on Milk Thistle Health Tonic market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1696243/covid-19-impact-on-milk-thistle-health-tonic-market

Segmental Analysis

The report has classified the global Covid-19 Impact on Milk Thistle Health Tonic industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Covid-19 Impact on Milk Thistle Health Tonic manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Covid-19 Impact on Milk Thistle Health Tonic industry.

Global Covid-19 Impact on Milk Thistle Health Tonic Market Segment By Type:

, Tablets, Capsules, Others

Global Covid-19 Impact on Milk Thistle Health Tonic Market Segment By Application:

Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc. Based on the Region:, Asia-Pacific (China, Japan, South Korea, India and ASEAN), North America (US and Canada), Europe (Germany, France, UK and Italy), Rest of World (Latin America, Middle East & Africa) Based on the Type:, Tablets, Capsules, Others Based on the Application:, Dietary Supplement, Health Food

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Covid-19 Impact on Milk Thistle Health Tonic industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Covid-19 Impact on Milk Thistle Health Tonic market include Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold, etc.

Key questions answered in the report:

Get Full Report in your inbox within 24 hours at USD(3250): https://www.qyresearch.com/settlement/pre/84e80cd1f8c8895c98fd4fdc22d8c304,0,1,covid-19-impact-on-milk-thistle-health-tonic-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Milk Thistle Health Tonic Industry1.7 COVID-19 Impact: Milk Thistle Health Tonic Market Trends 2 Global Milk Thistle Health Tonic Quarterly Market Size Analysis2.1 Milk Thistle Health Tonic Business Impact Assessment COVID-192.1.1 Global Milk Thistle Health Tonic Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.1.2 Global Milk Thistle Health Tonic Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Milk Thistle Health Tonic Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 Global Milk Thistle Health Tonic Quarterly Market Size by Manufacturers, 2019 VS 20203.2 Global Milk Thistle Health Tonic Factory Price by Manufacturers3.3 Location of Key Manufacturers Milk Thistle Health Tonic Manufacturing Factories and Area Served3.4 Date of Key Manufacturers Enter into Milk Thistle Health Tonic Market3.5 Key Manufacturers Milk Thistle Health Tonic Product Offered3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Milk Thistle Health Tonic Segments, By Type4.1 Introduction1.4.1 Tablets1.4.2 Capsules1.4.3 Others4.2 By Type, Global Milk Thistle Health Tonic Market Size, 2019-20214.2.1 By Type, Global Milk Thistle Health Tonic Market Size by Type, 2020-20214.2.2 By Type, Global Milk Thistle Health Tonic Price, 2020-2021 5 Impact of Covid-19 on Milk Thistle Health Tonic Segments, By Application5.1 Overview5.5.1 Dietary Supplement5.5.2 Health Food5.2 By Application, Global Milk Thistle Health Tonic Market Size, 2019-20215.2.1 By Application, Global Milk Thistle Health Tonic Market Size by Application, 2019-20215.2.2 By Application, Global Milk Thistle Health Tonic Price, 2020-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Health Genesis7.1.1 Health Genesis Business Overview7.1.2 Health Genesis Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.1.3 Health Genesis Milk Thistle Health Tonic Product Introduction7.1.4 Health Genesis Response to COVID-19 and Related Developments7.2 Pure Encapsulations7.2.1 Pure Encapsulations Business Overview7.2.2 Pure Encapsulations Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.2.3 Pure Encapsulations Milk Thistle Health Tonic Product Introduction7.2.4 Pure Encapsulations Response to COVID-19 and Related Developments7.3 Regis7.3.1 Regis Business Overview7.3.2 Regis Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.3.3 Regis Milk Thistle Health Tonic Product Introduction7.3.4 Regis Response to COVID-19 and Related Developments7.4 Solgar7.4.1 Solgar Business Overview7.4.2 Solgar Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.4.3 Solgar Milk Thistle Health Tonic Product Introduction7.4.4 Solgar Response to COVID-19 and Related Developments7.5 Aksuvital7.5.1 Aksuvital Business Overview7.5.2 Aksuvital Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.5.3 Aksuvital Milk Thistle Health Tonic Product Introduction7.5.4 Aksuvital Response to COVID-19 and Related Developments7.6 BEC7.6.1 BEC Business Overview7.6.2 BEC Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.6.3 BEC Milk Thistle Health Tonic Product Introduction7.6.4 BEC Response to COVID-19 and Related Developments7.7 NC7.7.1 NC Business Overview7.7.2 NC Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.7.3 NC Milk Thistle Health Tonic Product Introduction7.7.4 NC Response to COVID-19 and Related Developments7.8 Life Extension7.8.1 Life Extension Business Overview7.8.2 Life Extension Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.8.3 Life Extension Milk Thistle Health Tonic Product Introduction7.8.4 Life Extension Response to COVID-19 and Related Developments7.9 Swisse7.9.1 Swisse Business Overview7.9.2 Swisse Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.9.3 Swisse Milk Thistle Health Tonic Product Introduction7.9.4 Swisse Response to COVID-19 and Related Developments7.10 HerbsofGold7.10.1 HerbsofGold Business Overview7.10.2 HerbsofGold Milk Thistle Health Tonic Quarterly Production and Revenue, 20207.10.3 HerbsofGold Milk Thistle Health Tonic Product Introduction7.10.4 HerbsofGold Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis8.1 Milk Thistle Health Tonic Supply Chain Analysis8.1.1 Milk Thistle Health Tonic Supply Chain Analysis8.1.2 Covid-19 Impact on Milk Thistle Health Tonic Supply Chain8.2 Distribution Channels Analysis8.2.1 Milk Thistle Health Tonic Distribution Channels8.2.2 Covid-19 Impact on Milk Thistle Health Tonic Distribution Channels8.2.3 Milk Thistle Health Tonic Distributors8.3 Milk Thistle Health Tonic Customers 9 Key Findings 10 Appendix10.1 About Us10.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

The rest is here:
Covid-19 Impact on Milk Thistle Health Tonic Market 2020| Worldwide Industry Share, Size, Gross Margin, Trend, Future Demand, Analysis by Top Leading...

The report on the Cryonics Technology market provides a birds eye view of the current proceeding within the Cryonics Technology market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Cryonics Technology market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Cryonics Technology market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The recent published research report sheds light on critical aspects of the global Cryonics Technology market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Cryonics Technology market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Cryonics Technology market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2637235&source=atm

The recent published study includes information on key segmentation of the global Cryonics Technology market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Cryonics Technology market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Cryonics Technology market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Cryonics Technology Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2637235&source=atm

Global Cryonics Technology Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Cryonics Technology market. Key companies listed in the report are:

The key players covered in this studyPraxairCellulisCryologicsCryothermKrioRusVWRThermo Fisher ScientificCustom Biogenic SystemsOregon CryonicsAlcor Life Extension FoundationOsiris CryonicsSigma-AldrichSouthern Cryonics

Market segment by Type, the product can be split intoSlow freezingVitrificationUltra-rapidMarket segment by Application, split intoAnimal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Cryonics Technology status, future forecast, growth opportunity, key market and key players.To present the Cryonics Technology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Cryonics Technology are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Cryonics Technology Market by Geography:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2637235&licType=S&source=atm

Some of the Major Highlights of TOC covers in Cryonics Technology Market Report:

Chapter 1: Methodology & Scope of Cryonics Technology Market

Chapter 2: Executive Summary of Cryonics Technology Market

Chapter 3: Cryonics Technology Industry Insights

Chapter 4: Cryonics Technology Market, By Region

Chapter 5: Company Profile

And Continue

See original here:
Global trade impact of the Coronavirus Cryonics Technology Market Augmented Expansion to Be Registered by 2019-2049 - Latest Herald

CALGARY May 2, 2020 (Thomson StreetEvents) -- Edited Transcript of TC Energy Corp earnings conference call or presentation Friday, May 1, 2020 at 7:00:00pm GMT

* Donald R. Marchand

* Paul E. Miller

* Russell K. Girling

TransCanada PipeLines Limited - Executive VP, President of U.S. Natural Gas Pipelines & Diversity Officer

* Tracy A. Robinson

TC Energy Corporation - Executive VP & President of Canadian Natural Gas Pipelines

* Andrew M. Kuske

Crdit Suisse AG, Research Division - MD, Head of Canadian Equity Research, and Global Co-ordinator for Infrastructure Research

Tudor, Pickering, Holt & Co. Securities, Inc., Research Division - Director of Midstream Research

CIBC Capital Markets, Research Division - Executive Director of Institutional Equity Research

* Shneur Z. Gershuni

UBS Investment Bank, Research Division - Executive Director in the Energy Group and Analyst

Good afternoon, ladies and gentlemen. Welcome to the TC Energy 2020 First Quarter Results Conference Call.

I would now like to turn the meeting over to Mr. David Moneta, Vice President, Investor Relations. Please go ahead, Mr. Moneta.

Thank you, and thanks very much, and good afternoon, everyone. I'd like to welcome you to TC Energy's 2020 First Quarter Conference Call.

Joining me today are Russ Girling, President and Chief Executive Officer; Don Marchand, Executive Vice President, Strategy and Corporate Development and Chief Financial Officer; Franois Poirier, Chief Operating Officer and President, Power and Storage and Mexico; Tracy Robinson, President, Canadian Natural Gas Pipelines; Stan Chapman, President, U.S. Natural gas pipelines; Paul Miller, President, Liquids Pipelines; Bevin Wirzba, Senior Vice President, Liquids Pipelines; and Glenn Menuz, Vice President and Controller. Russ and Don will begin today with some opening comments on our financial results and certain other company developments.

A copy of the slide presentation that will accompany their remarks is available on our website. It can be found in the Investors section under the heading Events and Presentations.

Following their prepared remarks, we will take questions from the investment community. If you are a member of the media, please contact Jaimie Harding following this call and should be happy to address your questions.

In order to provide everyone from the investment community with an equal opportunity to participate, we ask that you limit yourself to 2 questions. If you have additional questions, please reenter the queue.

Also, we ask that you focus your questions on our industry, our corporate strategy, recent developments and key elements of our financial performance.

If you have detailed questions relating to some of our smaller operations, for your detailed financial models, Hunter and I would be pleased to discuss them with you following the call.

Before Russ begins, I'd like to remind you that our remarks today will include forward-looking statements that are subject to important risks and uncertainties. For more information on these risks and uncertainties, please see the reports filed by TC Energy with Canadian securities regulators and with the U.S. Securities and Exchange Commission.

And finally, during this presentation, we'll refer to measures such as comparable earnings per share, comparable earnings before interest, taxes, depreciation and amortization or comparable EBITDA and comparable funds generated from operations.

These and certain other comparable measures are considered to be non-GAAP measures. As a result, they may not be comparable to similar measures presented by other entities.

They are used to provide you with additional information on TC Energy's operating performance, liquidity and its ability to generate funds to finance its operations.

With that, I'll now turn the call over to Russ.

--------------------------------------------------------------------------------

Russell K. Girling, TC Energy Corporation - President, CEO & Director [3]

--------------------------------------------------------------------------------

Thank you, David, and good afternoon, everyone, and thank you all very much for joining us today.

Clearly, we're living in an unprecedented times with COVID-19, the pandemic having a significant impact on millions of people around the world. So on behalf of TC Energy, I'd like to start by expressing my sincere thanks to the frontline health care and other essential service workers who are risking their personal safety to ensure the well-being of others. Your selfless acts during this difficult time are truly courageous.

At TC Energy, as always, we too are focused on health and safety of our employees, our contractors and the communities in which we operate. When the World's Health Organization declared COVID-19 a global pandemic in early March, our business continuity plans were put in place across the organization, allowing us to continue to effectively operate our assets and execute on our capital programs.

The services we provide are broadly considered essential are critical in Canada, the United States and Mexico, given the important role our infrastructure plays in delivering energy to people across the continent. And at the responsibility we take very seriously, like many others, thousands of our employees are now working remotely, while those that must be physically at our work sites are following rigorous health, hygiene and distancing protocols.

I want to acknowledge and thank our employees and their families for their ongoing efforts to ensure the energy that is vital to the daily lives of so many continues to be delivered seamlessly across North America, and your efforts are truly making a difference.

Turning now to our first quarter financial results and certain other recent developments across our 3 core businesses, with approximately 95% of our comparable EBITDA coming from regulated or long-term contracted assets. We are largely insulated from the volatility associated with volume throughput and the commodity prices that are being experienced by many others.

Aside from the impact of normal maintenance activities and seasonal factors to date, we have not seen any meaningful change in the utilization of our assets, which further reinforces their critical nature to North America. As a result, as highlighted in our first quarter report, our $100 billion portfolio, high-quality, long life energy infrastructure assets continue to produce strong financial results.

And we continue to capitalize or we continue to realize the growth expected from our industry-leading capital program. Today, that program that we're advancing, it's $43 billion of secured capital projects, and it now includes Keystone XL.

In addition, we continue to advance more than $10 billion of projects under development, including the refurbishment of another 5 reactors at Bruce Power as part of their long-term life extension program. Over the last 4 months, we took significant steps to fund our 2020 capital expenditure program and to maintain our strong financial position despite challenging capital market conditions.

More specifically, we enhanced our liquidity by more than $9 billion through the issuance of long-term debt in both Canada and the United States at very attractive rates, the establishment of incremental committed credit facilities and the sale of 3 Ontario natural gas-fired power plants.

When combined with our predictable and growing cash flow from operations and the sale of a 65% interest in the Coastal GasLink project, which is scheduled to close in the second quarter, we believe that we're very well positioned to continue to fund our capital program and other obligations through a prolonged period of disruption in capital markets if that was to occur.

Looking forward, we expect our solid operating and financial performance to continue with 2020 comparable earnings per share is still anticipated to be similar to the recorded -- or the record results that we produced in 2019. While we're proud of our financial performance and the significant returns we've generated for our shareholders, we know that our ongoing success depends on our ability to balance profitability with safety and environmental and social responsibility.

We have a 65-year track record of safe and reliable operations, but we recognize that we can always improve. To keep you better informed, we have published several investor-focused ESG documents over the past year. They described some of the work we're doing to ensure our business remains resilient in an ever-evolving energy landscape. All of this can be found on our website at tcenergy.com.

With that as an overview, I'll explain some of the recent developments beginning with a brief review of our first quarter financial results. Don will provide more detail of our results and liquidity in just a few minutes.

Excluding certain specific items, comparable earnings were $1.1 billion or $1.18 per common share for the 3 months ended March 31 compared to $1 billion or $1.07 per share in 2019, which was an increase of 10% on a per share basis. Comparable EBITDA of $2.5 billion was 6% higher and the amount reported for the same period last year, while comparable funds generated from operations was $2.1 billion, which was 17% higher than the comparable period.

Each of these amounts reflects the strong performance of our legacy assets as well as contributions from another $1.6 billion of new long-term contracted and rate-regulated assets placed into service in early 2020.

Next, I'll make a few comments on our 3 core businesses, starting with our natural gas pipeline business. Customer demand for our services remained strong despite the COVID-19 impacts on the broader North American economy. Evidence of this can be seen in the volumes transported across our systems with the NGTL System field receipts averaging about 12.2 Bcf a day. The Canadian Mainline Western receipts averaging 3.2 Bcf a day. Our broader U.S. pipeline network moving approximately 26 Bcf a day, and our Mexican pipelines moving approximately 1.5 Bcf a day. Each of these amounts are similar to or greater than the volumes moved over the same period last year. At the same time, we continue to advance more than $27 billion of capital projects associated with our natural gas pipeline businesses.

The program includes significant expansion of our NGTL System, capacity additions of our -- to our U.S. network, the Villa de Reyes pipeline, the Tula project and our Coastal GasLink pipeline project in British Columbia, which will play an important role in delivering Canadian natural gas to Asian markets.

While it's too early to determine whether the COVID-19 pandemic will have any long-term impacts on our capital programs, what I would say is directionally, we would expect some slowdown of our construction activities in capital expenditure in 2020 because of the global health crisis and the impact, the COVID-related safety protocols will have on our construction productivity.

Finally, in natural gas pipelines, last week, we are pleased to announce a 5-year revenue requirement settlement with our customers on the NGTL System. The settlement, which runs from January 2020 through December 2024, sets a base equity return of 10.1% on 40% deemed common equity and includes incentive mechanisms for certain operating costs where variances from projected amounts would be shared between TC Energy and our customers.

The settlement was a result of a collaborative process between us and our customers and is responsive to their needs during this challenging time while providing us with a stable return as we invest billions of dollars in pipeline infrastructure to enhance their connectivity of natural gas supply to premium markets.

Turning now to our liquids pipeline business, which generated solid results during the first quarter, despite extraordinary volatility in global crude oil markets. While the volatility did have an impact on our market link and liquids marketing bigger businesses, Keystone continued to produce solid results as it serves an important market in the U.S. Midwest and Gulf Coast and is underpinned by long-term take-or-pay contracts with strong counterparties.

Also in Liquids Pipelines, we recently announced that we would commence construction of Keystone pipeline or the Keystone XL pipeline. Keystone XL is the fourth phase of the Keystone system and continues to be a very important project for both Canada and the United States. It will create thousands of jobs, advanced energy security for both nations in an environmentally and sustainable way. The project is underpinned by a new 20-year take-or-pay contracts that are expected to generate approximately USD 1.3 billion of incremental EBITDA on an annual basis once the pipeline is placed into service.

Keystone XL will require an additional investment of approximately USD 8 billion and is expected to enter service in 2023. To advance the project, we have entered into a partnership with the government of Alberta, who will invest approximately $1.1 billion of equity into the project and fully guarantee a USD 4.2 billion project level credit facility. Once the project is completed and placed into service, we expect to acquire the Alberta government's equity investment and refinance the credit facility.

We appreciate the ongoing backing of landowners, customers, indigenous groups and numerous other partners in the U.S. and Canada, who have helped us secure project support and key regulatory approvals for this very important energy infrastructure project.

In addition, I'd like to thank the many government officials across North America for their support without which this project could not have advanced.

Moving forward, we will continue to carefully manage various legal and regulatory matters as we construct this pipeline, which will have the capacity to move about 830,000 barrels a day of responsibly produced energy from the Canadian oil sands to the continent's largest refining market in the U.S. Gulf Coast.

Turning now to Power and Storage, where Bruce Power continued to produce solid results through the first 3 months of this year. After years of preparation, in January, Bruce Power commenced work on the Unit 6 Major Component Replacement, or MCR outage, when they took it off-line here in January. We expect to invest approximately $2.4 billion in that program as well as the ongoing asset management program through 2023 when the Unit 6 refurbishment is targeted to be done.

Unfortunately, because of COVID-19 on March 25, 2020, Bruce Power declared force majeure under its contract with the independent electric system operator. This force majeure notice covers the Unit 6 MCR and certain asset management work. At the time, the force majeure was declared, the Unit 6 MCR program was ahead of schedule.

Despite the force majeure, Bruce Power has been able to continue limited work on critical path activities as well as training for the MCR contractors. In late April, remobilization of the MCR workforce began with strict COVID-19 measures in place with respect to worker safety. The measures include shift adjustments to reduce headcount, increased personal protective equipment, physical distancing and a reduction in noncritical work.

Operations and planned outages on all other units are expected to continue as normal. Finally, in power, earlier this week, we completed the sale of 3 natural gas-fired power plants in Ontario, Napanee, Halton Hills and our interest in the Portlands Energy Center. Net proceeds of approximately $2.8 billion will be used to help fund our industry-leading capital program.

So in summary, today, we are advancing $43 billion secured growth projects that are expected to enter service by 2023. We have invested approximately $12 billion into this program to date with approximately $6 billion of these projects expected to be completed by the end of 2020. Notably, they are all underpinned by cost of service regulation or long-term contracts, giving us visibility to earnings and cash flow they will generate as they enter service.

Based on the strength of our recent financial performance and our promising outlook for the future, in February, TC Energy's Board of Directors declared a first quarter 2020 dividend of $0.81 per common share, which is equivalent to $3.24 on an annual basis. This represents an 8% increase over the amount declared for the same period in 2019 and is the 20th consecutive year that our Board of Directors has raised the dividend.

Over that same time frame, we have maintained consistently strong coverage ratios with our dividend, on average, representing a payout of approximately 80% of comparable earnings and 40% of comparable funds generated from operations leaving us with significantly internally-generated cash flow to invest in our businesses.

Based on the continued strong performance of our base business, the organic growth and the organic growth we expect to realize as we advance our $43 billion secured capital program, we expect our dividend to grow at an annual average rate of 8% to 10% through 2021 and 5% to 7% thereafter.

So in summary, I'd leave you with the following key messages. Today, we are a leading North American energy infrastructure company with a strong track record of delivering long-term shareholder value. Our assets provide an essential service to the functioning of the North American society and its economy and the demand for our services remain strong.

Looking forward, we have 5 significant platforms for growth: Canadian, U.S. and Mexican Natural Gas Pipelines, Liquids Pipelines and Power and Storage. As we advance our $43 billion secured capital program, we expect to build on our long track record of growing earnings, cash flow and dividends per share.

We have also more than $10 billion of projects in the advanced stages of development and expect numerous other in corridor organic growth opportunities to emanate from our extensive critical asset footprints.

Looking forward, (technical difficulty) working in accordance with our values and responding quickly to market signals and sign posts to ensure we remain industry-leading and resilient as we continue to grow shareholder value.

I'll now turn the call over to Don, who will provide more details on our first quarter results and our financial position. Don, over to you.

--------------------------------------------------------------------------------

Donald R. Marchand, TC Energy Corporation - Executive VP of Strategy & Corporate Development and CFO [4]

--------------------------------------------------------------------------------

Thanks, Russ. Good afternoon, everyone. As outlined in our results issued earlier today, net income attributable to common shares was $1.15 billion or $1.22 per share in the first quarter of 2020 compared to $1 billion or $1.09 per share for the same period in 2019.

First quarter results included a positive $281 million income tax valuation allowance release following our reassessment of deferred tax assets that are deemed more likely than not to be realized as a result of our decision to proceed with Keystone XL. This was partially offset by an incremental after-tax loss of $77 million related to the Ontario natural gas-fired power plants held for sale. First quarter 2019 also included certain specific items outlined on the slide and discussed further in our first quarter 2020 report to shareholders.

These specific items as well as unrealized gains and losses from changes in risk management activities are excluded from comparable earnings.

Comparable earnings in the first quarter rose by $122 million to $1.1 billion or $1.18 per share compared to $987 million or $1.07 per share in 2019, representing a 10% increase on a per share basis.

Turning to our business segment results on Slide 14. In the first quarter, comparable EBITDA from our 5 operating segments was $2.5 billion, a $152 million increase compared to 2019. Canadian Natural Gas Pipelines comparable EBITDA of $597 million was $41 million higher than the same period last year, primarily on account of increased rate base earnings as well as flow through depreciation and financial charges on the NGTL System from additional facilities placed in service. This was partially offset by lower flow through income taxes on both the NGTL System and the Canadian Mainline as a result of accelerated tax depreciation measures enacted by the Canadian federal government in June 2019.

NGTL System net income increased $22 million compared to first quarter 2019 as a result of a higher average investment base and continued system expansions and reflects an ROE of 10.1% on 40% deemed equity. Net income for the Canadian Mainline decreased $5 million year-over-year, largely due to lower incentive earnings.

U.S. natural gas pipelines comparable EBITDA of USD 766 million or CAD 1.032 billion in the quarter rose by USD 36 million or CAD 60 million compared to the same period in 2019. The increase was mainly due to contributions from Columbia Gas and Columbia Gulf growth projects placed in service, partially offset by the sale of certain Columbia midstream assets in August 2019.

Mexico Natural Gas pipelines comparable EBITDA of USD 198 million or CAD 269 million was USD 88 million or CAD 123 million above first quarter 2019. The increase was primarily due to higher earnings in Sur de Texas, including USD 55 million associated with onetime fees realized as a result of the successful completion of the project compared to contract targets as well as fees received from operating the pipeline.

Liquids Pipelines comparable EBITDA declined by $118 million to $445 million in first quarter 2020, driven by lower uncontracted volumes on the Keystone pipeline system, a decreased contribution from liquids marketing activities due to lower margins and reduced earnings as a result of the partial monetization of Northern Courier in July 2019.

Power and Storage comparable EBITDA rose by $43 million year-over-year to $194 million due to higher Bruce Power results, which were augmented by an increased realized power price and higher production resulting from fewer outage days, partially offset by losses on funds invested for post-retirement benefits.

The higher contribution from Bruce Power was modestly offset by lower Canadian power results, largely due to an outage at our Mackay River cogeneration facility, which began late fourth quarter 2019 and the sale of the Coolidge generating station in May 2019. For all our businesses with U.S. dollar-denominated income, including U.S. natural gas pipelines, Mexico Natural Gas Pipelines and parts of Liquids Pipelines, EBITDA was translated into Canadian dollars using an average exchange rate of CAD 1.34 in first quarter 2020 compared similar to the rate used for the same period in 2019.

As a reminder of our approach to managing foreign exchange exposure, our U.S. dollar-denominated revenue streams are partially hedged by interest on U.S. dollar-denominated debt. We then actively managed the residual exposure on a rolling 1-year forward basis with realized gains and losses on this program reflected in comparable interest income and other.

Now turning to the other income statement items on Slide 15. Depreciation and amortization of $630 million increased $22 million versus first quarter 2019, largely due to new projects placed in service in Canadian Natural Gas Pipelines and U.S. Natural Gas Pipelines. Depreciation of Canadian Natural Gas Pipelines is recoverable in tolls on a flow-through basis.

Interest expense of $578 million for first quarter 2020 was $8 million lower year-over-year, primarily due to the net effect of higher capitalized interest related to Coastal GasLink and Keystone XL, lower interest rates on higher levels of short-term borrowings and long-term debt issuances net of maturities.

AFUDC decreased $57 million for the 3 months ended March 31, 2020, compared to the same period in 2019, largely due to Columbia Gas growth projects placed in service during 2019 and the suspension of recording AFUDC effective January 1, 2020, on Tula due to continuing construction delays.

Comparable interest income and other increased by $19 million in the first quarter versus 2019, primarily due to unrealized foreign exchange gains on peso-denominated deferred income tax liabilities, reflecting the weakening of the Mexican peso in first quarter 2020.

Income tax expense included in comparable earnings was $211 million in first quarter 2020 compared to $228 million for the same period last year. The $17 million decrease was mainly due to lower flow-through income taxes on Canadian rate-regulated pipelines, inclusive of a lower Alberta corporate income tax rate, partially offset by lower foreign tax rate differentials and increased pretax earnings.

Excluding Canadian rate-regulated pipelines, where income taxes are a flow-through item and thus quite variable, along with equity AFUDC income in U.S. and Mexico Natural Gas Pipelines, we expect our 2020 full year effective tax rate to be in the mid- to high teens after normalizing for these items.

Comparable net income attributable to noncontrolling interest of $96 million in the first quarter decreased by $5 million related to the same period last year, primarily due to lower earnings in TC PipeLines, LP. And finally, preferred share dividends were comparable to first quarter 2019.

Now turning to Slide 16. During the first quarter, we invested approximately $2.3 billion in our capital program, which reflects 100% of Coastal GasLink spending pending close of the equity sale of the KKR and AIMCo expected in the second quarter. Capital expenditures were largely funded with comparable funds generated from operations of $2.1 billion, along with cash on hand and notes payable.

As everyone is acutely aware, capital market conditions have been significantly impacted by COVID-19, resulting in periods of dramatically heightened volatility and reduced liquidity. In response to this, we secured approximately $6.6 billion of additional financial capacity in early April through long-term debt issuances in Canada and the U.S. on compelling terms, along with the establishment of USD 2 billion of incremental committed credit facilities.

Our solid financial position was bolstered earlier this week with the completion of the disposition of our 3 Ontario natural gas-fired power plants for $2.8 billion.

The sale will result in a final estimated after-tax loss of $370 million, of which $271 million was realized at March 31, 2020. The remaining amount will be recorded on close and reflected in second quarter 2020 results.

These transactions have collectively added over $9 billion in incremental liquidity over the past months, enhancing our financial flexibility and demonstrating our continued access to capital markets under stressed market conditions.

Looking forward, our financial strength will improve further upon completing the partial monetization of and establishing project level financing for Coastal GasLink. In late April, we executed a credit agreement with the syndicate of banks extending nonrecourse project level financing to fund the majority of the project's construction costs.

The credit facilities will be available to be drawn once conditions precedent have been met, including the closing of the equity purchase agreement with KKR and AIMCo, which is expected to occur in the second quarter.

As was highlighted, we have also secured government of Alberta support for Keystone XL in the form of a USD 1.1 billion equity contribution and USD 4.2 billion loan guarantee.

Read this article:
Edited Transcript of TRP.TO earnings conference call or presentation 1-May-20 7:00pm GMT - Yahoo Finance

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

View post:
Biopharma Develops Antibody and Stem Cell Therapies in the Fight Against COVID-19 - JD Supra

Home Topics Lung Infection

Mesoblast announced data from a phase 2/3 trial evaluating remestemcel-L, an allogeneic mesenchymal stem cell product candidate, in ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS).

Remestemcel-L consists of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is believed to work by down-regulating the production of proinflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

The randomized, placebo-controlled trial is being conducted at Mount Sinai hospital in New York City. Patients were treated with a variety of experimental agents prior to receiving remestemcel-L. Findings from the study showed 83% survival in ventilator-dependent COVID-19 patients with moderate/severe ARDS (n=10/12) following 2 intravenous infusions of remestemcel-L within the first 5 days; 75% of patients (n=9/12) were able to successfully come off ventilator support at a median of 10 days. There have been 7 patients discharged from the hospital as of now.

Mesoblast Chief Executive Dr. Silviu Itescu stated: The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

Additionally, the Food and Drug Administration recently accepted for Priority Review the Biologics License Application of remestemcel-L for the treatment of steroid-refractory acute graft vs host disease. The Company expects to launch remestemcel-L in 2020 if approved.

For more information mesoblast.com.

This article originally appeared on MPR

Please login or register first to view this content.

LoginRegister

Next post in Lung InfectionClose

Continue reading here:
Remestemcel-L Looks Promising for COVID-19 With Moderate to Severe ARDS - Pulmonology Advisor

In an unfortunate development, actor Rishi Kapoor lost his long battle with Leukemia. As we all know, the actor had travelled to the US for his treatment earlier and came back looking younger and healed. But he has had his share of health issues ever since. The family had been referring to the treatment as marrow and today the family confirmed that the actor was struggling with leukemia. Let us first understand what leukemia is - Leukemia is cancer of the body's blood-forming tissues, which includes the bone marrow as well as the lymphatic system. There are several types of leukemia, and some even affect the children, however, mostly leukemia occurs in adults. According to Cancer.org, most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. . To understand the course of treatment that the actor may have undergone, we spoke exclusively to subject matter expert Dr Rahul Bhargava, Director, Haematology, Haemato - Oncology and Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram. The doctor says the way it appears, the star must have suffered from Acute myeloid leukemia (AML) which is a cancer that starts in the bone marrow, which is the soft inner part of certain bones, where the body makes new blood cells. This often quickly moves into the blood, as well. Talking about the treatment for this particular illness, Dr Bhargava said, There is a possibility that he underwent a MUD (Match unrelated donor) transplant with reduced intensity conditioning (RIC), which basically means that he was given a lower intensity treatment, considering his age. How does MUD work?In MUD, stem cells from outside are injected in the body, and mature stem cells are targeted and removed. A person has to be in the hospital for close to 21-25 days for this procedure and then we wait and see how the body responds to the treatment. The doctor adds that clearly the treatment couldnt control his disease and he succumbed to it.

See more here:
Rishi Kapoor succumbs to Leukemia: Here is all we know about the condition and treatment - Times of India

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Keeping in mind that there may never be an approach to totally stop or reverse aging, there have been some surprising disclosures to how Regenerative Medicine can naturally heal our body without the use of any surgical procedure.

Rejuvenating Old Cells to Healthy ones

The paces, stresses, and complexities in life drive us to age prematurely thereby breaking down our cells. Cell breakdown may lead to several health conditions like cancer, heart disease, Alzheimers and others.

Driving our bodies to age quickly, cell-breakdown is host to many age-related diseases, causing more than 100,000 deaths per day.

Dr David C Karli is an Ivy-trained physician, specialized in treating athletic injuries by inducing regenerative medicine and stem cell therapy in treatments.

He accepts the fact that patients can increase an additional 30 years of life by using Regenerative Medicine. One such innovation uses stem cells, however, there are issues with these cells.

They may not replace the original, diseased cells rapidly enough, or they may start to replicate uncontrollably, bringing about malignant growth.

Yet, Regenerative Medicine definitely guarantees the complete curing of a wide range of diseases, and ideally, slowing down the aging process too.

Stem Cell Therapy Programs with Promising Results

With solid funding and rapid advancements, one stem cell therapy that promises great outcomes is transfusions. In this therapy, stem cells are extracted from the patient and grown in cell culture to increase the number of cells. Following this, those cells are injected back into the patients body.

Dr. Karlis keen interest in Transfusions led him to create biologic products that can cause an age-related decline in a persons strength, endurance, and various other physical abilities.

At his biotech firm, Greyledge Technologies, biologic products are prepared by processing materials (blood or bone marrow) and implanting them into the human body to replicate the diseased tissues.

With an FDA-registered laboratory environment, the outcomes are promising and are an anti-aging protocol.

Telomeres may be the next-gen solution for Anti Aging

Telomeres are essential parts of our DNA that are connected to the premature aging cells. Situated at the end caps of our DNA strands, the information within Telomeres is lost while DNA replicates to the extent that they stop replicating.

If DNA replicates without losing information, scientists believe that Telomeres can significantly help to slow down the aging process.

Similar is the case with Metformin, a pharmaceutical reagent that improves wound healing. Proven to counteract aging, Metformin is now being tested for its unique ability to mimic calorie restriction.

Anti-Aging Through Regeneration

Utilizing induced tissue regeneration, this technology is a new approach to anti-aging treatment. Combining telomerase therapy and induced tissue regeneration, anti-aging through regeneration includes the study of the impact on age-related diseases like diabetes, metabolic disorders, cardiovascular disease, and others.

This technique focuses on the cells that are generated in our body during youth. As we age, these cells are lost and lead to a metabolic imbalance.

Scientists and Researchers are trying to find a way in which these cells can be restored to reverse the signs of aging and create a balance.

Humans have the ability to regenerate damaged and diseased tissues. However, this only happens during the first few weeks of development. With the help of Artificial Intelligence, scientists are trying to unlock this potential ability in humans.

The Future of Anti-Aging

With several breakthroughs on the horizon, cure-all promises and best outcomes, these anti-aging protocols have a long way to go.

While the introduction of regenerative medicine and stem cell therapies to redefine orthopedic treatment sounds like a miracle, there are still unexplored paths that need to be taken.

With all the benefits regenerative medicine has to offer, there will always be an eye on the never-ending search for the fountain of youth.

CLICK HERE FOR BREVARD COUNTY NEWS

Continued here:
Dr. David C. Karli's Opinion on Regenerative Medicine and Age Prevention | - SpaceCoastDaily.com

BACKGROUND:

Osteoporosisis a metabolic bone disease characterized by low bone density resulting in increased fracture susceptibility. This research was constructed to uncover the potential therapeutic application of osteoblasts transplantation, generated upon culturing male rat bone marrow-derived mesenchymal stem cells (BM-MSCs) in osteogenic medium (OM), OM containing gold (Au-NPs) or gold/hydroxyapatite (Au/HA-NPs) nanoparticles, in ovariectomized rats to counteractosteoporosis.

Forty rats were randomized into: (1) negative control, (2) osteoporotic rats, whereas groups (3), (4) and (5) constituted osteoporotic rats treated with osteoblasts yielded from culturing BM-MSCs in OM, OM plus Au-NPs or Au/HA-NPs, respectively. After 3months, osterix (OSX), bone alkaline phosphatase (BALP), sclerostin (SOST) and bone sialoprotein (BSP) serum levels were assessed. In addition, gene expression levels of cathepsin K, receptor activator of nuclear factor-b ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio were evaluated using real-time PCR. Moreover, histological investigation of femur bone tissues in different groups was performed. The homing of implanted osteoblasts to the osteoporotic femur bone of rats was documented by Sex determining region Y gene detection in bone tissue.

Our results indicated that osteoblasts infusion significantly blunted serum BALP, BSP and SOST levels, while significantly elevated OSX level. Also, they brought about significant down-regulation in gene expression levels of cathepsin K, RANKL and RANKL/OPG ratio versus untreated osteoporotic rats. Additionally, osteoblasts nidation could restore bone histoarchitecture.

These findings offer scientific evidence that transplanting osteoblasts in osteoporotic rats regains the homeostasis of the bone remodeling cycle, thus providing a promising treatment strategy for primaryosteoporosis.

Link:
Osteoblast-Based Therapy-A New Approach for Bone Repair in Osteoporosis: Pre-Clinical Setting - DocWire News

DetailsCategory: AntibodiesPublished on Saturday, 02 May 2020 12:42Hits: 143

- Innovative, fixed-dose formulation significantly reduces treatment time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to DARZALEX (daratumumab) for approved indications

- DARZALEX FASPRO is the only subcutaneous CD38-directed antibody approved in the treatment of multiple myeloma

HORSHAM, PA, USA I May 1, 2020 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. DARZALEX FASPRO is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.As a fixed-dose formulation, DARZALEX FASPRO can be administered over approximately three to five minutes, significantly less time than DARZALEX,which is given intravenously over hours. In the Phase 3 COLUMBA study supporting the approval, DARZALEX FASPRO demonstrated a consistent overall response rate (ORR) and pharmacokinetics and a similar safety profile compared with intravenous DARZALEX in patients with relapsed or refractory multiple myeloma. In addition, there was a nearly two-thirds reduction in systemic administration-related reactions (ARRs) for DARZALEX FASPRO compared to intravenous DARZALEX (13 percent vs. 34 percent, respectively).

"This approval exemplifies Janssen's mission and commitment to bringing together passion, science and ingenuity to advance novel solutions for patients," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. "We are excited about the potential of this meaningful innovation in transforming the treatment experience for patients with multiple myeloma where DARZALEX FASPRO can be administered in approximately three to five minutes, significantly less time than intravenous DARZALEX, which is given over hours. Based on its favorable profile, we are accelerating the development of DARZALEX FASPRO and evaluating its potential in multiple ongoing studies."

Click to Tweet: #NEWS: #FDA approves subcutaneous CD38-directed antibody for the treatment of multiple #myeloma. See here for more details: https://bit.ly/2VozhzY

The approval is based on data from the Phase 3 COLUMBA (MMY3012)and Phase 2 PLEIADES (MMY2040) studies.1,2 In the COLUMBA study, the ORR was non-inferior for patients taking DARZALEX FASPROas monotherapycompared to those taking intravenous DARZALEXas monotherapy (41 percent vs. 37 percent, respectively). In addition, there were fewer systemic ARRs with DARZALEX FASPRO versus intravenous DARZALEX (13 percent vs. 34 percent, respectively). In a pooled safety population of 490 patients who received DARZALEXFASPRO as monotherapy or in combination, the ARR rate wFas 11 percent. The safety profiles of intravenous DARZALEX and DARZALEX FASPRO were otherwise similar.1 Additionally, in the Phase 2 PLEIADES study evaluating the efficacy and safety of DARZALEX FASPRO in combination therapies, objective responses were demonstrated in combination with bortezomib, melphalan and prednisone (D-VMP) in newly diagnosed transplant ineligible patients. In addition, objective responses were demonstrated in combination with lenalidomide and dexamethasone (D-Rd) in relapsed or refractory patients who received one prior line of therapy.2

"The Multiple Myeloma Research Foundation shares a common goal with Janssen in advancing treatments for multiple myeloma and addressing the unmet needs of this patient community," said Paul Giusti, President and CEO of the Multiple Myeloma Research Foundation (MMRF). "The approval of DARZALEXFASPRO marks an important milestone which will help make a positive difference in the lives of patients who depend on this effective therapy."

Click to Tweet: .@theMMRF talks about advancing treatments for multiple #myeloma and addressing patient needs with latest #FDA approval. Read more here: https://bit.ly/2VozhzY

"Since the approval of daratumumab, a robust body of evidence has established its use as a treatment for multiple myeloma in both the frontline and relapsed and refractory settings," said Saad Z. Usmani, M.D., Division Chief of Plasma Cell Disorders, Levine Cancer Institute. "With DARZALEX FASPRO there may be fewer administration-related reactions compared to intravenous DARZALEX, providing an additional treatment option that may help patients, oncologists and nursing staff."

DARZALEX FASPROis co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme'sENHANZEdrug delivery technology].DARZALEX FASPRO will be available to patients and physicians as soon as the week of May 11, 2020. The intravenous DARZALEX formulation will also remain available as an option for patients and their physicians.

DARZALEX FASPROis approved in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant, in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy, as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

The U.S. FDA approval of DARZALEX FASPRO marks the first approval for this innovative subcutaneous formulation globally, and Janssen continues to work with health authorities around the world in an effort to bring this new treatment option to patients living with multiple myeloma.

Access to DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)Janssen offers comprehensive access and support information, resources and services to assist U.S. patients in gaining access to DARZALEX FASPROthrough the Janssen CarePath Program. Through the program, eligible commercial patients pay no more than $5 per injection, regardless of individual income level. Information on the enrollment process is available online atwww.CarePathSavingsProgram.com/DARZALEX.

For more information, healthcare providers or patients can contact: 1-844-55DARZA (1-844-553-2792). Information will also be available atwww.DARZALEX.com. Dedicated case coordinators are available to work with both healthcare providers and patients.

About the COLUMBA Study 1The randomized, open-label, multicenter Phase 3 COLUMBA study (MMY3012) included 522 patients (median age of 67 years) with multiple myeloma who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both a PI and an IMiD. In the arm that received DARZALEX FASPRO(n=263), patients received a fixed dose of DARZALEX FASPRO1,800 milligrams (mg), co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) 2,000 Units per milliliter (U/mL), subcutaneously weekly for Cycles 1 2, every two weeks for Cycles 3 6 and every four weeks for Cycle 7 and thereafter. In the intravenous DARZALEXarm (n=259), patients received DARZALEXfor intravenous infusion 16 milligrams per kilogram (mg/kg) weekly for Cycles 1 2, every two weeks for Cycles 3 6 and every four weeks for Cycle 7 and thereafter. Each cycle was 28 days. In the arm that received DARZALEX FASPRO, itwas given in a fixed volume of 15 mL over three to five minutes; the median injection time was five minutes. In the arm that received theintravenous administration, the median durations of the first, second and subsequent intravenous DARZALEXinfusions were 7.0, 4.3 and 3.4 hours, respectively.Patients in both arms continued treatment until disease progression or unacceptable toxicity.

About the PLEIADES Study 2The non-randomized, open-label, parallel assignment Phase 2 PLEIADES study (MMY2040) included more than 240 adults with multiple myeloma, including 67 patients with newly diagnosed multiple myeloma who were treated with 1,800 mg of DARZALEX FASPROin combination with bortezomib, melphalan, and prednisone (D-VMP) and 65 patients with relapsed or refractory disease who were treated with 1,800 mg of DARZALEX FASPROplus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd cohorts was overall response rate.

About DARZALEXand DARZALEX FASPROJanssen is committed to exploring the potential of DARZALEX (daratumumab) for patients with multiple myeloma across the spectrum of the disease. DARZALEX has been approved in seven indications, three of which are in the frontline setting, including newly diagnosed patients who are transplant eligible and ineligible.

DARZALEX has become a backbone therapy in the treatment of multiple myeloma, having been used in the treatment of more than 58,000 patients in the U.S. alone since its U.S. FDA approval in 2015. DARZALEX is the first CD38-directed antibody approved globally to treat multiple myeloma and in 2020, DARZALEX FASPRO(daratumumab and hyaluronidase human-fihj) follows as the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma.2

CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease.4 DARZALEX binds to CD38 and inhibits tumor cell growth causing myeloma cell death.5 DARZALEX may also have an effect on normal cells.3 Data across seven Phase 3 clinical trials, in both the frontline and relapsed settings, have shown that DARZALEX-based regimens resulted in significant improvement in progression-free survival and/or overall survival. 4,5,6,7,8,9,10,11 Additional studies are underway to assess the efficacy and safety of DARZALEXFASPRO in the treatment of other malignant and pre-malignant hematologic diseases in which CD38 is expressed, including smoldering myeloma and in amyloidosis.12,13

Key DARZALEX Milestones:

Please see full Prescribing Information at http://www.DARZALEX.com.

About Multiple MyelomaMultiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.21,22When damaged, these plasma cells rapidly spread and replace normal cells with tumors in the bone marrow. In 2020, it is estimated that 32,270 people will be diagnosed and 12,830 will die from the disease in the U.S.24 While some patients with multiple myeloma have no symptoms, most patients are diagnosed due to symptoms, which can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels, kidney problems or infections.23

Please see full Prescribing Information at http://www.DARZALEX.com.

About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at http://www.janssen.com. Follow us at http://www.twitter.com/JanssenGlobal. Janssen Research & Development, LLC and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

ENHANZEis a registered trademark of Halozyme.

1Mateos M-V et al. Efficacy and Safety of the Randomized, Open-Label, Non-inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (pts) With Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA. 2019 American Society of Clinical Oncology Annual Meeting. June 2019.

2Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.

32020Fedele G et al. CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFN Cytokines and Proliferation. Mediators Inflamm. 2013;564687.

4Janssen Research & Development, LLC. A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT02076009?term=mmy3003&rank=1 Identifier: NCT02136134 .

5Janssen Research & Development, LLC. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT02136134?term=mmy3004&rank=1 Identifier: NCT02076009.

6Janssen Research & Development, LLC. A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT02541383?term=mmy3006 Identifier: NCT02541383.

7Janssen Research & Development, LLC. A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT02195479?term=mmy3007&rank=1 Identifier: NCT02195479.

8Janssen Research & Development, LLC. Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT02252172?term=mmy3008&rank=1 Identifier: NCT02252172.

9Janssen Research & Development, LLC. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24]. Available at: https://clinicaltrials.gov/ct2/show/NCT03217812?term=MMY3011&rank=1 Identifier: NCT03217812.

10European Myeloma Network. Compare Progression Free Survival Btw Daratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24] Available at: https://clinicaltrials.gov/ct2/show/NCT03180736?term=MMY3013&rank=2 Identifier: NCT03180736

11Amgen. Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 July 24] Available at: https://clinicaltrials.gov/ct2/show/NCT03158688?term=NCT03158688&rank=1 Identifier: NCT03158688.

12Janssen Research & Development, LLC. A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 March 19]. Available at: https://clinicaltrials.gov/ct2/show/NCT02316106?term=smm2001&rank=1 Identifier: NCT02316106.

13Janssen Research & Development, LLC. An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2018 March 19]. Available at: https://clinicaltrials.gov/ct2/show/NCT02413489?term=lym2001&rank=1 Identifier: NCT02413489

14Janssen Biotech, Inc. "Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab." Issued August 30, 2012.

15Janssen Biotech, Inc. "DARZALEX (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma." Issued November 16, 2015.

16Janssen Biotech, Inc. "DARZALEX (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy." Issued November 21, 2016.

17Janssen Biotech, Inc. "DARZALEX (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies." Issued June 16, 2017.

18Janssen Biotech, Inc. "Janssen Announces DARZALEX (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible." Issued May 7, 2018.

19Janssen Biotech, Inc. "Janssen Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible." Issued June 27, 2019.

20Janssen Biotech, Inc. "Janssen Announces U.S. FDA Approval of DARZALEX (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma." Issued September 26, 2019.

21Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.

22American Cancer Society. "What Is Multiple Myeloma?" Available at: http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed June 2019.

23American Cancer Society. "Key Statistics About Multiple Myeloma." Available at: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html. Accessed January 2020.

SOURCE: Janssen

Link:
US Food and Drug Administration Approves DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the...

Stem Cell Therapy market describes in-depth assessments and professional studies of the current and future status of the market worldwide, including valuable facts and figures. Stem Cell Therapy markets enhance this growth trend by providing information on new opportunities and market drivers, trends and future technologies. This report defines scope, coverage, production and CAGR (%) according to type, share, revenue status and outlook, capacity, consumption, market drivers, production status and outlook and opportunities, exports, imports, emerging market / national growth rates. This report provides a 360-degree overview of the industrys competitive environment. The Stem Cell Therapy market report evaluates key regions (countries) with a large market share during the forecast period.

Get sample copy of Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691

The research in its endeavor to present an unbiased presentation of the Stem Cell Therapy market, complete with multi-faceted documentation of various market forces that collectively lend enormous growth impetus to the Stem Cell Therapy market. This report further reinforces vital statistical data on technological marvels that under prevailing circumstances direct growth in the Stem Cell Therapy market. A holistic understanding on PESTEL and SWOT analysis are also tagged in the report to unearth peculiarities of the Stem Cell Therapy market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Furthermore, Report provides the deep analysis about the impact of domestic and global players on market, trade regulation, value chain optimization, and opportunities analysis for new present as well as new players, recent developments, strategic market growth analysis, area marketplace expanding, product launches, technological innovations and many more. The study report of global Stem Cell Therapy market can be split on the basis of key segments such as product type, application, key companies and key regions. Also the growth of the global Stem Cell Therapy market can be projected on the basis of segments and calculation for sales by application and type of the product in terms of volume and value.

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

This market ready research offering on Stem Cell Therapy market is a go-to synopsis that highlights on all the core developments simultaneously dominant across all regional hubs in the Stem Cell Therapy market and their subsequent implications on holistic growth trajectory of Stem Cell Therapy market globally. The report is aimed at answering all the relevant queries pertaining to the target market based on which successful business decisions could be rapidly applied, favoring uncompromised growth in the Stem Cell Therapy market.

The report also lends light on competition spectrum, highlighting core market participants who are identified as frontline players in Stem Cell Therapy market as highlighted by this research. In its bid to equip players with real time understanding of the various operational factors dominant across regions, the research elaborating on Stem Cell Therapy market also houses crucial data on various geographical hubs identified in Stem Cell Therapys market as presented.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

Thursday, May 7, 2020, 8:30 a.m. EDT

NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc.(NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a conference call to update shareholders on financial results for the first quarter endedMarch 31, 2020, and provide a corporate update, at 8:30 a.m, Eastern Daylight Time, onThursday, May 7, 2020.

BrainStorms CEO,Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will beRalph Kern, MD, MHSc, President and Chief Medical Officer, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer andPreetam Shah, PhD, MBA, Executive Vice President and Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to:q@brainstorm-cell.com. Questions should be submitted by5:00 p.m. EDT, Tuesday, May 5, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 1Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

ABOUT NUROWNNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

ABOUT BRAINSTORM CELL THERAPEUTICS INC.:BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in theU.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

SAFE HARBOR STATEMENT:Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Story continues

More:
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update - Yahoo Finance